

Modulation of structured polypeptide specificity

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are specific for the human protease plasma Kallikrein and are modified in one or two peptide loops to enhance potency and/or protease resistance.

Cyclic peptides are able to bind with high affinity and target specificity to protein targets and hence are an attractive molecule class for the development of therapeutics. In fact, several cyclic peptides are already successfully used in the clinic, as for example the antibacterial peptide vancomycin, the immunosuppressant drug cyclosporine or the anti-cancer drug octreotide (Driggers, et al., *Nat Rev Drug Discov* 2008, 7 (7), 608-24). Good binding properties result from a relatively large interaction surface formed between the peptide and the target as well as the reduced conformational flexibility of the cyclic structures. Typically, macrocycles bind to surfaces of several hundred square angstrom, as for example the cyclic peptide CXCR4 antagonist CVX15 (400 Å²; Wu, B., et al., *Science* 330 (6007), 1066-71), a cyclic peptide with the Arg-Gly-Asp motif binding to integrin αVβ3 (355 Å²) (Xiong, J. P., et al., *Science* 2002, 296 (5565), 151-5) or the cyclic peptide inhibitor upain-1 binding to urokinase-type plasminogen activator (603 Å²; Zhao, G., et al., *J Struct Biol* 2007, 160 (1), 1-10).

Due to their cyclic configuration, peptide macrocycles are less flexible than linear peptides, leading to a smaller loss of entropy upon binding to targets and resulting in a higher binding affinity. The reduced flexibility also leads to locking target-specific conformations, increasing binding specificity compared to linear peptides. This effect has been exemplified by a potent and selective inhibitor of matrix metalloproteinase 8, MMP-8) which lost its selectivity over other MMPs when its ring was opened (Cherney, R. J., et al., *J Med Chem* 1998, 41 (11), 1749-51). The favorable binding properties achieved through macrocyclization are even more pronounced in multicyclic peptides having more than one peptide ring as for example in vancomycin, nisin or actinomycin.

Different research teams have previously tethered polypeptides with cysteine residues to a synthetic molecular structure (Kemp, D. S. and McNamara, P. E., *J. Org. Chem*, 1985; Timmerman, P. et al., *ChemBioChem*, 2005). Meloen and co-workers had used tris(bromomethyl)benzene and related molecules for rapid and quantitative cyclisation of multiple peptide loops onto synthetic scaffolds for structural mimicry of protein surfaces (Timmerman, P. et al., *ChemBioChem*, 2005). Methods for the generation of candidate

drug compounds wherein said compounds are generated by linking cysteine containing polypeptides to a molecular scaffold as for example tris(bromomethyl)benzene are disclosed in WO 2004/077062 and WO 2006/078161.

5 WO2004/077062 discloses a method of selecting a candidate drug compound. In particular, this document discloses various scaffold molecules comprising first and second reactive groups, and contacting said scaffold with a further molecule to form at least two linkages between the scaffold and the further molecule in a coupling reaction.

10 WO2006/078161 discloses binding compounds, immunogenic compounds and peptidomimetics. This document discloses the artificial synthesis of various collections of peptides taken from existing proteins. These peptides are then combined with a constant synthetic peptide having some amino acid changes introduced in order to produce combinatorial libraries. By introducing this diversity via the chemical linkage to separate peptides featuring various amino acid changes, an increased opportunity to find the desired binding activity is provided. Figure 1 of this document shows a schematic
15 representation of the synthesis of various loop peptide constructs. The constructs disclosed in this document rely on -SH functionalised peptides, typically comprising cysteine residues, and heteroaromatic groups on the scaffold, typically comprising benzylic halogen substituents such as bis- or tris-bromophenylbenzene. Such groups react to form a thioether linkage between the peptide and the scaffold.

20 We recently developed a phage display-based combinatorial approach to generate and screen large libraries of bicyclic peptides to targets of interest (Heinis, et al., *Nat Chem Biol* 2009, 5 (7), 502-7; see also international patent application WO2009/098450). Briefly, combinatorial libraries of linear peptides containing three cysteine residues and two regions of six random amino acids (Cys-(Xaa)₆-Cys-(Xaa)₆-Cys) were displayed on
25 phage and cyclised by covalently linking the cysteine side chains to a small molecule (tris-(bromomethyl)benzene). Bicyclic peptides isolated in affinity selections to the human proteases cathepsin G and plasma Kallikrein (PK) had nanomolar inhibitory constants. The best inhibitor, PK15, inhibits human PK (hPK) with a K_i of 3 nM. Similarities in the amino acid sequences of several isolated bicyclic peptides suggested that both peptide
30 loops contribute to the binding. PK15 did not inhibit rat PK (81% sequence identity) nor the homologous human serine proteases factor XIa (hfXIa; 69% sequence identity) or thrombin (36% sequence identity) at the highest concentration tested (10 µM) (Heinis, et al., *Nat Chem Biol* 2009, 5 (7), 502-7). This finding suggested that the bicyclic inhibitor is highly specific and that other human trypsin-like serine proteases will not be inhibited. A

synthetic, small peptidic inhibitor such as PK15 having the above described potency and target selectivity has potential application as a therapeutic to control PK activity in hereditary angioedema, a life-threatening disease which is characterized by recurrent episodes of edema or to prevent contact activation in cardiopulmonary bypass surgery.

- 5 The peptide PK15 was isolated from a library based on the peptide PK2, H-ACSDRFRNCPLWSGTCTG-NH₂, in which the second 6-amino acid loop was randomised. The sequence of PK15 was H-ACSDRFRNCPADEALCTG-NH₂, and the IC₅₀ binding constant for human Kallikrein was 1.7 nM.

Summary of the Invention

- 10 We have analysed kallikrein-binding reagents in order to optimise binding affinity and activity. In our copending unpublished patent application PCT/EP2012/069898, selective bicyclic peptide ligands which are Inhibitors of human plasma kallikrein have been described.

- In one embodiment described therein, the loops of the peptide ligand comprise five amino acids and a first loop comprises the motif $G_r x^W /_F P x^K /_R G_r$, wherein G_r is a reactive group.
- 15 In the present context, the reference to a “first” loop does not necessarily denote a particular position of the loop in a sequence. In some embodiments, however, the first loop may be proximal loop in an amino terminus to carboxy terminus peptide sequence. For example, the polypeptide further comprises a second, distal loop which comprises the
 - 20 motif $G_r^T /_L H^Q /_T x L G_r$. Examples of sequences of the first loop include $G_r x W P A R G_r$, $G_r x W P S R G_r$, $G_r x F P F R G_r$ and $G_r x F P Y R G_r$. In these examples, x may be any amino acid, but is for example S or R.


For example, the polypeptide may be one of the polypeptides set forth in Table 4, Table 5 or Table 6.

- 25 The reactive group can be a reactive amino acid. For example, the reactive amino acid is cysteine.

- Variants of the polypeptides can be prepared by identifying those residues which are available for mutation and preparing libraries which include mutations at those positions. For example, the polypeptide 06-56 in Table 4, Figures 5, 6 can be mutated without loss
- 30 of activity at positions Q4 and T10 (see Examples below). Polypeptide ligands comprising mutations at these positions can be selected which have improved binding activity in comparison with 06-56.

For a kallikrein-inhibiting bicycle, it is pertinent to obtain an adequate protease stability profile, such that it has a low protease-driven clearance in plasma or other relevant environments. In a rapid comparative plasma stability assay (Method #1) that observed the progressive disappearance of parent peptide in rat plasma, it was found that the N-terminal alanine (which is present at the time of selections and was originally included in synthetic peptides of lead sequences) is rapidly removed across all bicycle sequences tested by both rat and human plasma. This degradation was avoided by synthesising a lead candidate lacking both N- and C-terminal alanines. To remove potential recognition points for amino- and carboxypeptidases, the free amino-terminus that now resides on Cys 1 of the lead candidate is capped with acetic anhydride during peptide synthesis, leading to a molecule that is N-terminally acetylated. In an equal measure, the C-terminal cysteine is synthesised as the amide so as to remove a potential recognition point for carboxypeptidases.

Thus, in one example Bicyclic lead candidates have the following generic sequence:



where "Ac" refers to N-terminal acetylation, "-NH₂" refers to C-terminal amidation, where "C₁, C₂, C₃" refers to the first, second and third cysteine in the sequence, where "AA₁" to "AA_n" refers to the position of the amino acid (whose nature "AA" is defined by the selections described above), and where "(TMB)" indicates that the peptide sequence has been cyclised with TBMB (tribromomethylbenzene) or any other suitable reactive scaffold.

In this context, the lead peptides "Ac-(06-34-18)(TMB)" and "Ac-(06-34-18)(TMB) Phe2 Tyr4" have the sequences Ac-CSWPARCLHQDLC-NH₂ and Ac-CSFPYRCLHQDLC-NH₂, respectively. These can be numbered according to the above scheme as

- 1) Ac-C₁S₁W₂P₃A₄R₅C₂L₆H₇Q₈D₉L₁₀C₃-NH₂
denoted as Ac-(06-34-18)(TMB)
- 2) Ac-C₁S₁F₂P₃Y₄R₅C₂L₆H₇Q₈D₉L₁₀C₃-NH₂
denoted as Ac-(06-34-18)(TMB) Phe2 Tyr4

where the invariant cysteines are underlined. These peptides have been characterised in detail, and shown to have sub-nanomolar potency against kallikrein, with very favourable

selectivity profiles towards kallikrein-homologous proteins, while retaining good cross-reactivity towards rat kallikrein. The latter is valuable for establishing pharmacodynamics in animal models.

5 The unmodified peptide Ac-06-34-18(TMB)-NH₂ has a half-life of 2.3 hrs in rat plasma, while that of Ac-06-34-18(TMB)-NH₂ Phe2 Tyr4 is slightly shorter, at 0.9 hrs (Table 1). In an effort to identify the proteolytic recognition site(s) in Ac-06-34-18(TMB)-NH₂, the peptide was sampled in rat plasma over time (method #1), and each sample was analysed for the progressive appearance of peptide fragments using MALDI-TOF mass spectrometry. This revealed Arg5 in Loop 1 to be the main site of protease recognition
10 and subsequent peptide degradation.

A process of chemical synthesis was undertaken to identify Arginine5 substitutes that would sufficiently protect the peptide from rat plasma protease degradation. It was found that removal of Arg 5 in loop 1, or replacement of the Arg side chain with any non-charged or charged chemical entities, enhances the stability of the peptide ligand.

15 Moreover, the proteolytic stability is enhanced by chemical modification of the peptide bonds N- or C-terminally adjacent to Arg5. The chemical modification is, for example, α -N-alkylation, or modification of the peptide bond with its reduced amide form.

In one embodiment, proteolytic stability is enhanced by steric obstruction of nearby amino acids to Arg5. For example, the steric obstruction results from α -N-alkylation.

20 These Bicyclic Peptide candidates were then evaluated for the following characteristics:

- 1) maintenance of potency against human kallikrein (seeking a K_i of 10 nM or lower)
- 2) maintenance of potency against rat kallikrein (seeking a K_i of 50 nM or lower)
- 3) enhanced stability in rat plasma (greater t_{1/2} desirable compared to the wildtype peptide)
- 25 4) maintenance of selectivity profile against other kallikrein-related enzymes and proteins.

In the course of the investigations in PCT/EP2012/069898, it was determined that the following Arginine modifications or mimics fulfilled the 4 above criteria, these being

a) 4-guanidylphenylalanine (4-GuanPhe: t_{1/2} increase in rat plasma: 1-5 fold);

b) homoarginine (HArg: $t_{1/2}$ increase in rat plasma: ~2-5-fold); and

c) α -N-methylarginine (NMe-Arg: $t_{1/2}$ increase in rat plasma: >10-fold)

We have found that certain non-natural amino acids permit binding to plasma Kallikrein with nM K_i , whilst increasing residence time in plasma significantly. The data are summarized in Table 1 and Figure 17.

Moreover, PCT/EP2012/069898 also disclosed an additional modification at position 3 in 06-34-18, where the proline was replaced with azetidine carboxylic acid (Aze3). This modification, likely due to its greater constraint and reduced entropy, invariably enhances the potency of an 06-34-18-based peptide by a factor of 2 to 5 (Table 1). In combination with the stability enhancing modifications at Arg 5 (specifically, HArg, NMe-Arg and 4GuanPhe), more potent Bicyclic Peptide derivatives are obtained.

Exemplary non-natural amino acids are selected from N-methyl Arginine, homo-arginine and hydroxyproline. N-methyl and homo-derivatives of Arginine are used to replace Arginine, and proline 3 can be replaced by, for example, hydroxyproline, azetidine carboxylic acid, or an α -substituted amino acid, such as aminoisobutyric acid. In another embodiment, arginine may be replaced with guanidyl-phenylalanine.

In one embodiment, the polypeptide comprises a first loop which comprises the motif G_rWPARG_r , wherein P is replaced with azetidine carboxylic acid; and/or R is replaced with N-methyl arginine; and/or R is replaced with homoarginine; and/or R is replaced with guanidyl-phenylalanine.

In one embodiment, the polypeptide comprises a first loop which comprises the motif G_rFPYRG_r , wherein R is replaced with N-methyl arginine; and/or R is replaced with homoarginine, and wherein proline is replaced by azetidine carboxylic acid; and/or R is replaced with guanidyl-phenylalanine.

We have now developed the approaches used in PCT/EP2102/069898, and set forth herein, as applied to the optimization of the second loop. In accordance with the present invention, we have identified an additional protease recognition site in loop 2, which is located at Histidine 7 in the 06-34-18 sequence. This residue is in particular recognised by proteases contained in ex vivo human plasma. Moreover, this site is also recognised by rat membrane-bound proteases as determined in an in vivo rat pharmacokinetic study. Thus, for 06-34-18 to attain a suitable pharmacokinetic stability profile as required for therapeutic purposes, both protease recognition sites (Arg5 in Loop1 and His7 in Loop2)

have to be stabilised such that the peptide is resistant to human plasma proteases, and the proteolytically aggressive environment encountered both in vivo in rat and human.

Accordingly, in a first aspect, the present invention provides a peptide ligand specific for human Kallikrein comprising a polypeptide comprising at least three reactive groups, separated by at least two loop sequences, and a molecular scaffold which forms covalent bonds with the reactive groups of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold, wherein the loops of the peptide ligand comprises five amino acids and one loop comprises the motif $G_r^T/LH^Q/TxLG_r$.

In the context of peptide 06-34-18, this loop is the second loop, positioned C-terminal to a first loop.

For example, the motif is $G_rxHxDLG_r$, wherein G_r is a reactive group. For example, the motif $G_rTHxxLG_r$.

In one embodiment, two adjacent loops of the polypeptide comprise the motif $G_rx^W/FPx^K/RG_r^T/LH^Q/TDLG_r$.

Examples of such polypeptides are set forth in Table 4, Table 5 or Table 6.

In a second aspect, the invention relates to a peptide ligand as described in the first aspect of the invention, wherein removal of His 7 in loop 2, or replacement of the histidine side chain with any non-charged or charged chemical entities, enhances the stability of the peptide ligand.

For example, proteolytic stability is enhanced by chemical modification of the peptide bonds N- or C-terminally adjacent to His7. The chemical modification is, for example, α -N-alkylation, or modification of the peptide bond with its reduced amide form.

In one embodiment, proteolytic stability is enhanced by steric obstruction of nearby amino acids to His 7. For example, the steric obstruction results from replacement of position 9 with its D- amino acid enantiomer, or α -N-alkylation.

In another embodiment, proteolytic stability is enhanced by introduction of sterically obstructive amino acids at position 6. For example, proteolytic stability is enhanced by introduction of C β -derivatised amino acids such as phenylglycine or cyclohexylglycine at position 6, which enhance the potency of the peptide ligand sequence towards human plasma kallikrein and reduce the proteolytic hydrolysis of the C-terminal peptide bond.

The teaching of the present invention may be combined with the teaching of PCT/EP2012/06989, such that the polypeptide according to the invention can comprise a first loop which comprises the motif $G_r x W P A R G_r$ or $G_r x F P Y R G_r$ and a second loop comprising the motif $G_r^T /_L H^Q /_T x L G_r$.

- 5 In one example, in the first loop Pro 3 is replaced with azetidine carboxylic acid; and/or Arg 5 is replaced with N-methyl arginine; and/or Arg 5 is replaced with homoarginine; and/or Arg 5 is replaced with guanidylphenylalanine.

Brief description of the figures

- 10 **Figure 1** Phage selection of bicyclic peptides. (a) Bicyclic peptide phage libraries. Random amino acids are indicated as 'X', alanine as 'A' and the constant three cysteine residues as 'C'. (b) Format of chemically synthesized bicyclic peptide structures having loops of 3, 5 or 6 amino acids. The structures are generated by linking linear peptides via three cysteine side chains to tris-(bromomethyl)benzene (TBMB). Amino acids that vary in the bicyclic peptides are indicated with 'Xaa'. (c-e) Sequences of bicyclic peptides isolated from library 5x5 (c), library 3x3 A (d) and library 3x3 B (e). Similarities in amino acids are highlighted by shading.

- Figure 2** Comparison of the surface amino acids of hPK and homologous serine proteases. (a) Structure of hPK (PDB entry 2ANW) with surface representation. Atoms of amino acids being exposed to the surface and closer than 4, 8 and 12 Å to benzamidine (in grey) bound to the S1 pocket are stained more darkly. (b) Structure of hPK. The side chains of amino acids that are different in hfXla are highlighted. (c) Structure of hPK. The side chains of amino acids that are different in rPK are highlighted.

- Figure 3** Pictorial representation of the method used for determination of preferred residues for mutation in polypeptide ligands

Figure 4 Analysis of amino acid substitutions in peptide 06-34 (Table 4) on the binding of the peptide to plasma Kallikrein at 2nM. For each position, the effect of various mutations at that position is shown, in comparison to the parent sequence.

- Figure 5** Analysis of amino acid substitutions in peptide 06-56 (Table 4) on the binding of the peptide to plasma Kallikrein at 2nM. For each position, the effect of various mutations at that position is shown, in comparison to the parent sequence.

Figure 6 Analysis of amino acid substitutions in peptide 06-56 (Table 4) on the binding of the peptide to plasma Kallikrein at 10nM. For each position, the effect of various mutations at that position is shown, in comparison to the parent sequence.

Figure 7 Mass spectrometric output showing the mass spectra of Ac-06-34-18(TMB)-NH₂ after exposure to 35% rat plasma, at t₀, 1 day, 2 days and 3 days (method #1). Mass accuracies vary somewhat due to interfering ions and low concentrations of fragments; however identification of discrete proteolytic fragments is possible.

Figure 8 Chemical structures of metabolites M1, M2, M3 of Ac-06-34-18(TMB)-NH₂ identified after exposure to rat plasma.

Figure 9 Chemical structure of the Ac-06-34-18(TMB)-NH₂ lead

Figure 10 Enzyme inhibition assay of Kallikrein by the Ac-06-34-18(TMB)-NH₂ lead and its 1st loop scrambled derivatives. A dramatic reduction in affinity is observed, underlining the importance of the integrity of the WPAR pharmacophore.

Figure 11 Chemical structures of arginine and its analogues.

Figure 12 Chemical structures of Trp and potential hydrophobic analogues

Figure 13 Chemical structures of Pro and potential constrained analogues

Figure 14 Comparative Kallikrein inhibition by Aze3, NMeArg5 and doubly modified Ac-06-34-18(TMB)-NH₂.

Figure 15 Chemical structures of Alanine and derivatives thereof

Figure 16 Comparative Kallikrein inhibition by F2Y4, F2Y4 HR5 and doubly modified Ac-06-34-18(TMB)-NH₂.

Figure 17 Chemical structures of Loop1 modifications in Ac-(06-34-18) that impart favorable rat plasma stability and/or potency enhancement (Aze3 in place of Pro3, 4GuanPhe in place of Arg5, HArg in place of Arg5, NMe-Arg5 in place of Arg5).

Figure 18a Wildtype peptide is subjected to human plasma. Note the appearance of fragments with His7-Gln8, Leu6, and Leu6-His7-Gln8 removed. Due to the nature of MALDI-TOF, the intensity of the signals is not quantitative. The possible hydrolysis sites in the sequence are indicated with the arrows in the diagram, with the direction of subsequent degradation indicated by the horizontal arrows above the sequence.

Figure 18b Arg5 N-methylated 06-34-18 is subjected to human plasma. This peptide has enhanced stability in rat plasma. In human plasma, however, the peptide is not stable, as exemplified by the appearance of fragments lacking His7-Gln8, Leu6, and Leu6-His7-Gln8 in Loop2. Due to the nature of MALDI-TOF, the intensity of the signals is not quantitative.

Figure 19a Chemical Structure of Loop 2 of 06-34-18

Figure 19b Summary of structures employed at position 6 in Loop 2. The non-standard amino acid acronyms are defined in the Methods and Table 7.

Figure 19c Summary of structures employed at position 7 in Loop 2. The non-standard amino acid acronyms are defined in the Methods and Table 7.

Figure 19d Summary of structures employed at position 8 in Loop 2. The non-standard amino acid acronyms are defined in the Methods and Table 7.

Figure 20a Structure of N-His Peptoid within Loop 2 of 06-34-18. A homohistidine side chain was introduced on the N α , while C α loses its chiral center.

Figure 20b Structure of the reduced amide between position 6 and 7 in Loop 2 of 06-34-18. The methylene in place of the carbonyl removes the scissile peptide bond.

Figure 21a Comparative stability of wildtype (06-34-18) at t = 0, 21 and 46 hrs in human plasma.

Figure 21b Comparative stability of wildtype (06-34-18) at t = 0, 21 and 46 hrs in rat plasma.

Figure 21c Comparative stability of (06-34-18) Phe2 Aze3 Tyr4 HArg5 D-Asp9 at t = 0, 21 and 46 hrs in human plasma.

Figure 21d Comparative stability of Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 Ala(ψ CH₂NH)₆ at t = 0, 21 and 46 hrs in human plasma.

Figure 21e Comparative stability of Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 Ala(ψ CH₂NH)₆ at t = 0, 21 and 46 hrs in rat plasma.

Figure 22 Full chemical structure of Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 Ala(ψ CH₂NH)₆. All amino acids are in the L-enantiomeric form.

Figure 23 Rat pharmacokinetic analysis of peptides Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 Ala(ψ CH₂NH)₆ and Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 D-Asp9 compared to the proteolytically stable but pharmacologically inert all-D enantiomer of Ac-(06-34-18). Note the clearance of Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 Ala(ψ CH₂NH)₆ is closely resembling that of the D amino acid control peptide "Ac-(06-34-18) all D". The horizontal dotted lines indicate the limit of quantification for each of the respective peptides.

10 Detailed Description of the Invention

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art, such as in the arts of peptide chemistry, cell culture and phage display, nucleic acid chemistry and biochemistry. Standard techniques are used for molecular biology, genetic and biochemical methods (see Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd ed., 2001, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Ausubel et al., Short Protocols in Molecular Biology (1999) 4th ed., John Wiley & Sons, Inc.), which are incorporated herein by reference.

A peptide ligand, as referred to herein, refers to a peptide covalently bound to a molecular scaffold. Typically, such peptides comprise two or more reactive groups which are capable of forming covalent bonds to the scaffold, and a sequence subtended between said reactive groups which is referred to as the loop sequence, since it forms a loop when the peptide is bound to the scaffold. In the present case, the peptides comprise at least three reactive groups, and form at least two loops on the scaffold.

The reactive groups are groups capable of forming a covalent bond with the molecular scaffold. Typically, the reactive groups are present on amino acid side chains on the peptide. Examples are amino-containing groups such as cysteine, lysine and selenocysteine.

Specificity, in the context herein, refers to the ability of a ligand to bind or otherwise interact with its cognate target to the exclusion of entities which are similar to the target. For example, specificity can refer to the ability of a ligand to inhibit the interaction of a human enzyme, but not a homologous enzyme from a different species. Using the

approach described herein, specificity can be modulated, that is increased or decreased, so as to make the ligands more or less able to interact with homologues or paralogues of the intended target. Specificity is not intended to be synonymous with activity, affinity or avidity, and the potency of the action of a ligand on its target (such as, for example, binding affinity or level of inhibition) are not necessarily related to its specificity.

Binding activity, as used herein, refers to quantitative binding measurements taken from binding assays, for example as described herein. Therefore, binding activity refers to the amount of peptide ligand which is bound at a given target concentration.

Multispecificity is the ability to bind to two or more targets. Typically, binding peptides are capable of binding to a single target, such as an epitope in the case of an antibody, due to their conformational properties. However, peptides can be developed which can bind to two or more targets; dual specific antibodies, for example, as known in the art as referred to above. In the present invention, the peptide ligands can be capable of binding to two or more targets and are therefore be multispecific. For example, they bind to two targets, and are dual specific. The binding may be independent, which would mean that the binding sites for the targets on the peptide are not structurally hindered by the binding of one or other of the targets. In this case both targets can be bound independently. More generally it is expected that the binding of one target will at least partially impede the binding of the other.

There is a fundamental difference between a dual specific ligand and a ligand with specificity which encompasses two related targets. In the first case, the ligand is specific for both targets individually, and interacts with each in a specific manner. For example, a first loop in the ligand may bind to a first target, and a second loop to a second target. In the second case, the ligand is non-specific because it does not differentiate between the two targets, for example by interacting with an epitope of the targets which is common to both.

In the context of the present invention, it is possible that a ligand which has activity in respect of, for example, a target and an orthologue, could be a bispecific ligand. However, in one embodiment the ligand is not bispecific, but has a less precise specificity such that it binds both the target and one or more orthologues. In general, a ligand which has not been selected against both a target and its orthologue is less likely to be bispecific as a result of modulation of loop length.

If the ligands are truly bispecific, in one embodiment at least one of the target specificities of the ligands will be common amongst the ligands selected, and the level of that specificity can be modulated by the methods disclosed herein. Second or further specificities need not be shared, and need not be the subject of the procedures set forth
5 herein.

A target is a molecule or part thereof to which the peptide ligands bind or otherwise interact with. Although binding is seen as a prerequisite to activity of most kinds, and may be an activity in itself, other activities are envisaged. Thus, the present invention does not require the measurement of binding directly or indirectly.

10 The molecular scaffold is any molecule which is able to connect the peptide at multiple points to impart one or more structural features to the peptide. It is not a cross-linker, in that it does not merely replace a disulphide bond; instead, it provides two or more attachment points for the peptide. Suitably, the molecular scaffold comprises at least three attachment points for the peptide, referred to as scaffold reactive groups. These
15 groups are capable of reacting to the reactive groups on the peptide to form a covalent bond. Preferred structures for molecular scaffolds are described below.

Screening for binding activity (or any other desired activity) is conducted according to methods well known in the art, for instance from phage display technology. For example, targets immobilised to a solid phase can be used to identify and isolate binding members
20 of a repertoire. Screening allows selection of members of a repertoire according to desired characteristics.

The term library refers to a mixture of heterogeneous polypeptides or nucleic acids. The library is composed of members, which are not identical. To this extent, library is synonymous with repertoire. Sequence differences between library members are
25 responsible for the diversity present in the library. The library may take the form of a simple mixture of polypeptides or nucleic acids, or may be in the form of organisms or cells, for example bacteria, viruses, animal or plant cells and the like, transformed with a library of nucleic acids. Under some conditions, each individual organism or cell contains only one or a limited number of library members.

30 In one embodiment, the nucleic acids are incorporated into expression vectors, in order to allow expression of the polypeptides encoded by the nucleic acids. In a preferred aspect, therefore, a library may take the form of a population of host organisms, each organism containing one or more copies of an expression vector containing a single member of the

library in nucleic acid form which can be expressed to produce its corresponding polypeptide member. Thus, the population of host organisms has the potential to encode a large repertoire of genetically diverse polypeptide variants.

In one embodiment, a library of nucleic acids encodes a repertoire of polypeptides. Each nucleic acid member of the library typically has a sequence related to one or more other members of the library. By related sequence is meant an amino acid sequence having at least 50% identity, for example at least 60% identity, for example at least 70% identity, for example at least 80% identity, for example at least 90% identity, for example at least 95% identity, for example at least 98% identity, for example at least 99% identity to at least one other member of the library. Identity can be judged across a contiguous segment of at least 3 amino acids, for example at least 4, 5, 6, 7, 8, 9 or 10 amino acids, for example at least 12 amino acids, for example at least 14 amino acids, for example at least 16 amino acids, for example at least 17 amino acids or the full length of the reference sequence.

A repertoire is a collection of variants, in this case polypeptide variants, which differ in their sequence. Typically, the location and nature of the reactive groups will not vary, but the sequences forming the loops between them can be randomised. Repertoires differ in size, but should be considered to comprise at least 10^2 members. Repertoires of 10^{11} or more members can be constructed.

A set of polypeptide ligands, as used herein, refers to a plurality of polypeptide ligands which can be subjected to selection in the methods described. Potentially, a set can be a repertoire, but it may also be a small collection of polypeptides, from at least 2 up to 10, 20, 50, 100 or more.

A group of polypeptide ligands, as used herein, refers to two or more ligands. In one embodiment, a group of ligands comprises only ligands which share at least one target specificity. Typically, a group will consist of from at least 2, 3, 4, 5, 6, 7, 8, 9 or 10, 20, 50, 100 or more ligands. In one embodiment, a group consists of 2 ligands.

(A) Construction of Peptide Ligands

(i) Molecular scaffold

Molecular scaffolds are described in, for example, WO2009098450 and references cited therein, particularly WO2004077062 and WO2006078161.

As noted in the foregoing documents, the molecular scaffold may be a small molecule, such as a small organic molecule.

In one embodiment the molecular scaffold may be, or may be based on, natural monomers such as nucleosides, sugars, or steroids. For example the molecular scaffold
5 may comprise a short polymer of such entities, such as a dimer or a trimer.

In one embodiment the molecular scaffold is a compound of known toxicity, for example of low toxicity. Examples of suitable compounds include cholesterol, nucleotides, steroids, or existing drugs such as tamazepam.

In one embodiment the molecular scaffold may be a macromolecule. In one embodiment
10 the molecular scaffold is a macromolecule composed of amino acids, nucleotides or carbohydrates.

In one embodiment the molecular scaffold comprises reactive groups that are capable of reacting with functional group(s) of the polypeptide to form covalent bonds.

The molecular scaffold may comprise chemical groups as amines, thiols, alcohols,
15 ketones, aldehydes, nitriles, carboxylic acids, esters, alkenes, alkynes, azides, anhydrides, succinimides, maleimides, alkyl halides and acyl halides.

In one embodiment, the molecular scaffold may comprise or may consist of tris(bromomethyl)benzene, especially 1,3,5-Tris(bromomethyl)benzene ('TBMB'), or a derivative thereof.

20 In one embodiment, the molecular scaffold is 2,4,6-Tris(bromomethyl)mesitylene. It is similar to 1,3,5-Tris(bromomethyl)benzene but contains additionally three methyl groups attached to the benzene ring. This has the advantage that the additional methyl groups may form further contacts with the polypeptide and hence add additional structural constraint.

25 The molecular scaffold of the invention contains chemical groups that allow functional groups of the polypeptide of the encoded library of the invention to form covalent links with the molecular scaffold. Said chemical groups are selected from a wide range of functionalities including amines, thiols, alcohols, ketones, aldehydes, nitriles, carboxylic acids, esters, alkenes, alkynes, anhydrides, succinimides, maleimides, azides, alkyl
30 halides and acyl halides.

(ii) Polypeptide

The reactive groups of the polypeptides can be provided by side chains of natural or non-natural amino acids. The reactive groups of the polypeptides can be selected from thiol groups, amino groups, carboxyl groups, guanidinium groups, phenolic groups or hydroxyl groups. The reactive groups of the polypeptides can be selected from azide, keto-carbonyl, alkyne, vinyl, or aryl halide groups. The reactive groups of the polypeptides for linking to a molecular scaffold can be the amino or carboxy termini of the polypeptide.

In some embodiments each of the reactive groups of the polypeptide for linking to a molecular scaffold are of the same type. For example, each reactive group may be a cysteine residue. Further details are provided in WO2009098450.

In some embodiments the reactive groups for linking to a molecular scaffold may comprise two or more different types, or may comprise three or more different types. For example, the reactive groups may comprise two cysteine residues and one lysine residue, or may comprise one cysteine residue, one lysine residue and one N-terminal amine.

Cysteine can be employed because it has the advantage that its reactivity is most different from all other amino acids. Scaffold reactive groups that could be used on the molecular scaffold to react with thiol groups of cysteines are alkyl halides (or also named halogenoalkanes or haloalkanes). Examples are bromomethylbenzene (the scaffold reactive group exemplified by TBMB) or iodoacetamide. Other scaffold reactive groups that are used to couple selectively compounds to cysteines in proteins are maleimides. Examples of maleimides which may be used as molecular scaffolds in the invention include: tris-(2-maleimidoethyl)amine, tris-(2-maleimidoethyl)benzene, tris-(maleimido)benzene. Selenocysteine is also a natural amino acid which has a similar reactivity to cysteine and can be used for the same reactions. Thus, wherever cysteine is mentioned, it is typically acceptable to substitute selenocysteine unless the context suggests otherwise.

Lysines (and primary amines of the N-terminus of peptides) are also suited as reactive groups to modify peptides on phage by linking to a molecular scaffold. However, they are more abundant in phage proteins than cysteines and there is a higher risk that phage particles might become cross-linked or that they might lose their infectivity. Nevertheless, it has been found that lysines are especially useful in intramolecular reactions (e.g. when a molecular scaffold is already linked to the phage peptide) to form a second or

consecutive linkage with the molecular scaffold. In this case the molecular scaffold reacts preferentially with lysines of the displayed peptide (in particular lysines that are in close proximity). Scaffold reactive groups that react selectively with primary amines are succinimides, aldehydes or alkyl halides. In the bromomethyl group that is used in a number of the accompanying examples, the electrons of the benzene ring can stabilize the cationic transition state. This particular aryl halide is therefore 100-1000 times more reactive than alkyl halides. Examples of succinimides for use as molecular scaffold include tris-(succinimidyl aminotriacetate), 1,3,5-Benzenetriacetic acid. Examples of aldehydes for use as molecular scaffold include Triformylmethane. Examples of alkyl halides for use as molecular scaffold include 1,3,5-Tris(bromomethyl)-2,4,6-trimethylbenzene, 1,3,5-Tris(bromomethyl) benzene, 1,3,5-Tris(bromomethyl)-2,4,6-triethylbenzene.

The amino acids with reactive groups for linking to a molecular scaffold may be located at any suitable positions within the polypeptide. In order to influence the particular structures or loops created, the positions of the amino acids having the reactive groups may be varied by the skilled operator, e.g. by manipulation of the nucleic acid encoding the polypeptide in order to mutate the polypeptide produced. By such means, loop length can be manipulated in accordance with the present teaching.

For example, the polypeptide can comprise the sequence $AC(X)_nC(X)_mCG$, wherein X stands for a random natural amino acid, A for alanine, C for cysteine and G for glycine and n and m, which may be the same or different, are numbers between 3 and 6.

(iii) Reactive groups of the polypeptide

The molecular scaffold of the invention may be bonded to the polypeptide via functional or reactive groups on the polypeptide. These are typically formed from the side chains of particular amino acids found in the polypeptide polymer. Such reactive groups may be a cysteine side chain, a lysine side chain, or an N-terminal amine group or any other suitable reactive group. Again, details may be found in WO2009098450.

Examples of reactive groups of natural amino acids are the thiol group of cysteine, the amino group of lysine, the carboxyl group of aspartate or glutamate, the guanidinium group of arginine, the phenolic group of tyrosine or the hydroxyl group of serine. Non-natural amino acids can provide a wide range of reactive groups including an azide, a keto-carbonyl, an alkyne, a vinyl, or an aryl halide group. The amino and carboxyl group

of the termini of the polypeptide can also serve as reactive groups to form covalent bonds to a molecular scaffold/molecular core.

The polypeptides of the invention contain at least three reactive groups. Said polypeptides can also contain four or more reactive groups. The more reactive groups are used, the more loops can be formed in the molecular scaffold.

In a preferred embodiment, polypeptides with three reactive groups are generated. Reaction of said polypeptides with a molecular scaffold/molecular core having a three-fold rotational symmetry generates a single product isomer. The generation of a single product isomer is favourable for several reasons. The nucleic acids of the compound libraries encode only the primary sequences of the polypeptide but not the isomeric state of the molecules that are formed upon reaction of the polypeptide with the molecular core. If only one product isomer can be formed, the assignment of the nucleic acid to the product isomer is clearly defined. If multiple product isomers are formed, the nucleic acid cannot give information about the nature of the product isomer that was isolated in a screening or selection process. The formation of a single product isomer is also advantageous if a specific member of a library of the invention is synthesized. In this case, the chemical reaction of the polypeptide with the molecular scaffold yields a single product isomer rather than a mixture of isomers.

In another embodiment of the invention, polypeptides with four reactive groups are generated. Reaction of said polypeptides with a molecular scaffold/molecular core having a tetrahedral symmetry generates two product isomers. Even though the two different product isomers are encoded by one and the same nucleic acid, the isomeric nature of the isolated isomer can be determined by chemically synthesizing both isomers, separating the two isomers and testing both isomers for binding to a target ligand.

In one embodiment of the invention, at least one of the reactive groups of the polypeptides is orthogonal to the remaining reactive groups. The use of orthogonal reactive groups allows the directing of said orthogonal reactive groups to specific sites of the molecular core. Linking strategies involving orthogonal reactive groups may be used to limit the number of product isomers formed. In other words, by choosing distinct or different reactive groups for one or more of the at least three bonds to those chosen for the remainder of the at least three bonds, a particular order of bonding or directing of specific reactive groups of the polypeptide to specific positions on the molecular scaffold may be usefully achieved.

In another embodiment, the reactive groups of the polypeptide of the invention are reacted with molecular linkers wherein said linkers are capable to react with a molecular scaffold so that the linker will intervene between the molecular scaffold and the polypeptide in the final bonded state.

- 5 In some embodiments, amino acids of the members of the libraries or sets of polypeptides can be replaced by any natural or non-natural amino acid. Excluded from these exchangeable amino acids are the ones harbouring functional groups for cross-linking the polypeptides to a molecular core, such that the loop sequences alone are exchangeable. The exchangeable polypeptide sequences have either random
10 sequences, constant sequences or sequences with random and constant amino acids. The amino acids with reactive groups are either located in defined positions within the polypeptide, since the position of these amino acids determines loop size.

- In one embodiment, an polypeptide with three reactive groups has the sequence $(X)_l Y(X)_m Y(X)_n Y(X)_o$, wherein Y represents an amino acid with a reactive group, X
15 represents a random amino acid, m and n are numbers between 3 and 6 defining the length of intervening polypeptide segments, which may be the same or different, and l and o are numbers between 0 and 20 defining the length of flanking polypeptide segments.

- Alternatives to thiol-mediated conjugations can be used to attach the molecular scaffold
20 to the peptide via covalent interactions. Alternatively these techniques may be used in modification or attachment of further moieties (such as small molecules of interest which are distinct from the molecular scaffold) to the polypeptide after they have been selected or isolated according to the present invention – in this embodiment then clearly the attachment need not be covalent and may embrace non-covalent attachment. These
25 methods may be used instead of (or in combination with) the thiol mediated methods by producing phage that display proteins and peptides bearing unnatural amino acids with the requisite chemical reactive groups, in combination small molecules that bear the complementary reactive group, or by incorporating the unnatural amino acids into a chemically or recombinantly synthesised polypeptide when the molecule is being made
30 after the selection/isolation phase. Further details can be found in WO2009098450 or Heinis, et al., *Nat Chem Biol* **2009**, 5 (7), 502-7.

(iv) Combination of loops to form multispecific molecules

Loops from peptide ligands, or repertoires of peptide ligands, are advantageously combined by sequencing and de novo synthesis of a polypeptide incorporating the combined loops. Alternatively, nucleic acids encoding such polypeptides can be synthesised.

Where repertoires are to be combined, particularly single loop repertoires, the nucleic acids encoding the repertoires are advantageously digested and re-ligated, to form a novel repertoire having different combinations of loops from the constituent repertoires. Phage vectors can include polylinkers and other sites for restriction enzymes which can provide unique points for cutting and relegation the vectors, to create the desired multispecific peptide ligands. Methods for manipulating phage libraries are well known in respect of antibodies, and can be applied in the present case also.

(v) Attachment of Effector Groups and Functional Groups

Effector and/or functional groups can be attached, for example, to the N or C termini of the polypeptide, or to the molecular scaffold.

Appropriate effector groups include antibodies and parts or fragments thereof. For instance, an effector group can include an antibody light chain constant region (CL), an antibody CH1 heavy chain domain, an antibody CH2 heavy chain domain, an antibody CH3 heavy chain domain, or any combination thereof, in addition to the one or more constant region domains. An effector group may also comprise a hinge region of an antibody (such a region normally being found between the CH1 and CH2 domains of an IgG molecule).

In a further preferred embodiment of this aspect of the invention, an effector group according to the present invention is an Fc region of an IgG molecule. Advantageously, a peptide ligand-effector group according to the present invention comprises or consists of a peptide ligand Fc fusion having a $t_{1/2}$ half-life of a day or more, two days or more, 3 days or more, 4 days or more, 5 days or more, 6 days or more or 7 days or more. Most advantageously, the peptide ligand according to the present invention comprises or consists of a peptide ligand Fc fusion having a $t_{1/2}$ half-life of a day or more.

Functional groups include, in general, binding groups, drugs, reactive groups for the attachment of other entities, functional groups which aid uptake of the macrocyclic peptides into cells, and the like.

The ability of peptides to penetrate into cells will allow peptides against intracellular targets to be effective. Targets that can be accessed by peptides with the ability to penetrate into cells include transcription factors, intracellular signalling molecules such as tyrosine kinases and molecules involved in the apoptotic pathway. Functional groups which enable the penetration of cells include peptides or chemical groups which have been added either to the peptide or the molecular scaffold. Peptides such as those derived from such as VP22, HIV-Tat, a homeobox protein of *Drosophila* (Antennapedia), e.g. as described in Chen and Harrison, *Biochemical Society Transactions* (2007) Volume 35, part 4, p821 "Cell-penetrating peptides in drug development: enabling intracellular targets" and "Intracellular delivery of large molecules and small peptides by cell penetrating peptides" by Gupta et al. in *Advanced Drug Discovery Reviews* (2004) Volume 57 9637. Examples of short peptides which have been shown to be efficient at translocation through plasma membranes include the 16 amino acid penetratin peptide from *Drosophila* Antennapedia protein (Derossi et al (1994) *J Biol. Chem.* Volume 269 p10444 "The third helix of the Antennapedia homeodomain translocates through biological membranes"), the 18 amino acid 'model amphipathic peptide' (Oehlke et al (1998) *Biochim Biophys Acts* Volume 1414 p127 "Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically") and arginine rich regions of the HIV TAT protein. Non peptidic approaches include the use of small molecule mimics or SMOCs that can be easily attached to biomolecules (Okuyama et al (2007) *Nature Methods* Volume 4 p153 'Small-molecule mimics of an α -helix for efficient transport of proteins into cells'. Other chemical strategies to add guanidinium groups to molecules also enhance cell penetration (Elson-Scwab et al (2007) *J Biol Chem* Volume 282 p13585 "Guanidinylated Neomycin Delivers Large Bioactive Cargo into cells through a heparin Sulphate Dependent Pathway"). Small molecular weight molecules such as steroids may be added to the molecular scaffold to enhance uptake into cells.

One class of functional groups which may be attached to peptide ligands includes antibodies and binding fragments thereof, such as Fab, Fv or single domain fragments. In particular, antibodies which bind to proteins capable of increasing the half life of the peptide ligand in vivo may be used.

RGD peptides, which bind to integrins which are present on many cells, may also be incorporated.

In one embodiment, a peptide ligand-effector group according to the invention has a $t_{1/2}$ half-life selected from the group consisting of: 12 hours or more, 24 hours or more, 2 days or more, 3 days or more, 4 days or more, 5 days or more, 6 days or more, 7 days or more, 8 days or more, 9 days or more, 10 days or more, 11 days or more, 12 days or more, 13 days or more, 14 days or more, 15 days or more or 20 days or more. Advantageously a peptide ligand-effector group or composition according to the invention will have a $t_{1/2}$ half life in the range 12 to 60 hours. In a further embodiment, it will have a $t_{1/2}$ half-life of a day or more. In a further embodiment still, it will be in the range 12 to 26 hours.

- Functional groups include drugs, such as cytotoxic agents for cancer therapy. These include Alkylating agents such as Cisplatin and carboplatin, as well as oxaliplatin, mechlorethamine, cyclophosphamide, chlorambucil, ifosfamide; Anti-metabolites including purine analogs azathioprine and mercaptopurine)) or pyrimidine analogs; plant alkaloids and terpenoids including vinca alkaloids such as Vincristine, Vinblastine, Vinorelbine and Vindesine; Podophyllotoxin and its derivatives etoposide and teniposide; Taxanes, including paclitaxel, originally known as Taxol; topoisomerase inhibitors including camptothecins: irinotecan and topotecan, and type II inhibitors including amsacrine, etoposide, etoposide phosphate, and teniposide. Further agents can include Antitumour antibiotics which include the immunosuppressant dactinomycin (which is used in kidney transplantations), doxorubicin, epirubicin, bleomycin and others.

Possible effector groups also include enzymes, for instance such as carboxypeptidase G2 for use in enzyme/prodrug therapy, where the peptide ligand replaces antibodies in ADEPT.

(vi) Synthesis

- It should be noted that once a polypeptide of interest is isolated or identified according to the present invention, then its subsequent synthesis may be simplified wherever possible. Thus, groups or sets of polypeptides need not be produced by recombinant DNA techniques. For example, the sequence of polypeptides of interest may be determined, and they may be manufactured synthetically by standard techniques followed by reaction with a molecular scaffold *in vitro*. When this is performed, standard chemistry may be used since there is no longer any need to preserve the functionality or integrity of the genetically encoded carrier particle, such as phage. This enables the rapid large scale preparation of soluble material for further downstream experiments or validation. In this regard, large scale preparation of the candidates or leads identified by the methods of the

present invention could be accomplished using conventional chemistry such as that disclosed in Timmerman et al.

Thus, the invention also relates to manufacture of polypeptides or conjugates selected as set out herein, wherein the manufacture comprises optional further steps as explained
5 below. In one embodiment, these steps are carried out on the end product polypeptide/conjugate made by chemical synthesis, rather than on the phage.

Optionally amino acid residues in the polypeptide of interest may be substituted when manufacturing a conjugate or complex e.g. after the initial isolation/identification step.

Peptides can also be extended, to incorporate for example another loop and therefore
10 introduce multiple specificities.

To extend the peptide, it may simply be extended chemically at its N-terminus or C-terminus or within the loops using orthogonally protected lysines (and analogues) using standard solid phase or solution phase chemistry. Standard protein chemistry may be used to introduce an activatable N- or C-terminus. Alternatively additions may be made
15 by fragment condensation or native chemical ligation e.g. as described in (Dawson PE, Muir TW, Clark-Lewis I, Kent, SBH. 1994. Synthesis of Proteins by Native Chemical Ligation. Science 266:776-779), or by enzymes, for example using subtiligase as described in (Subtiligase: a tool for semisynthesis of proteins Chang TK, Jackson DY, Burnier JP, Wells JA Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12544-8 or in
20 Bioorganic & Medicinal Chemistry Letters Tags for labelling protein N-termini with subtiligase for proteomics Volume 18, Issue 22, 15 November 2008, Pages 6000-6003 Tags for labeling protein N-termini with subtiligase for proteomics; Hikari A.I. Yoshihara, Sami Mahrus and James A. Wells).

Alternatively, the peptides may be extended or modified by further conjugation through
25 disulphide bonds. This has the additional advantage of allowing the first and second peptide to dissociate from each other once within the reducing environment of the cell. In this case, the molecular scaffold (eg. TBMB) could be added during the chemical synthesis of the first peptide so as to react with the three cysteine groups; a further cysteine could then be appended to the N-terminus of the first peptide, so that this
30 cysteine only reacted with a free cysteine of the second peptide.

Similar techniques apply equally to the synthesis/coupling of two bicyclic and bispecific macrocycles, potentially creating a tetraspecific molecule.

Furthermore, addition of other functional groups or effector groups may be accomplished in the same manner, using appropriate chemistry, coupling at the N- or C-termini or via side chains. In one embodiment, the coupling is conducted in such a manner that it does not block the activity of either entity.

5 (vii) Peptide modification

To develop the bicyclic peptides (Bicycles; peptides conjugated to molecular scaffolds) into a suitable drug-like molecule, whether that be for injection, inhalation, nasal, ocular, oral or topical administration, a number of properties need considered. The following at least need to be designed into a given lead Bicycle:

- 10 • protease stability, whether this concerns Bicycle stability to plasma proteases, epithelial ("membrane-anchored") proteases, gastric and intestinal proteases, lung surface proteases, intracellular proteases and the like. Protease stability should be maintained between different species such that a Bicycle lead candidate can be developed in animal models as well as administered with confidence to
- 15 humans.
- replacement of oxidation-sensitive residues, such as tryptophan and methionine with oxidation-resistant analogues in order to improve the pharmaceutical stability profile of the molecule
- a desirable solubility profile, which is a function of the proportion of charged and
- 20 hydrophilic versus hydrophobic residues, which is important for formulation and absorption purposes
- correct balance of charged versus hydrophobic residues, as hydrophobic residues influence the degree of plasma protein binding and thus the concentration of the free available fraction in plasma, while charged residues (in particular arginines)
- 25 may influence the interaction of the peptide with the phospholipid membranes on cell surfaces. The two in combination may influence half-life, volume of distribution and exposure of the peptide drug, and can be tailored according to the clinical endpoint. In addition, the correct combination and number of charged versus hydrophobic residues may reduce irritation at the injection site (were the peptide
- 30 drug administered subcutaneously).
- a tailored half-life, depending on the clinical indication and treatment regimen. It may be prudent to develop an unmodified molecule for short exposure in an acute

illness management setting, or develop a bicyclic peptide with chemical modifications that enhance the plasma half-life, and hence be optimal for the management of more chronic disease states.

Approaches to stabilise therapeutic peptide candidates against proteolytic degradation are numerous, and overlap with the peptidomimetics field (for reviews see Gentilucci et al, Curr. Pharmaceutical Design, (2010), 16, 3185-203, and Nestor et al, Curr. Medicinal Chem (2009), 16, 4399-418).

These include

- Cyclisation of peptide
- N- and C-terminal capping, usually N-terminal acetylation and C-terminal amidation.
- Alanine scans, to reveal and potentially remove the proteolytic attack site(s).
- D-amino acid replacement, to probe the steric requirements of the amino acid side chain, to increase proteolytic stability by steric hindrance and by a propensity of D-amino acids to stabilise β -turn conformations (Tugyi *et al* (2005) PNAS, 102(2), 413–418).
- N-methyl/N-alkyl amino acid replacement, to impart proteolytic protection by direct modification of the scissile amide bond (Fiacco *et al*, Chembiochem. (2008), 9(14), 2200–3). N-methylation also has strong effect on the torsional angles of the peptide bond, and is believed to aid in cell penetration & oral availability (Biron *et al* (2008), Angew. Chem. Int. Ed., 47, 2595 –99)
- Incorporation of non-natural amino acids, i.e. by employing
 - Isosteric/isoelectronic side chains that are not recognised by proteases, yet have no effect on target potency
 - Constrained amino acid side chains, such that proteolytic hydrolysis of the nearby peptide bond is conformationally and sterically impeded. In particular, these concern proline analogues, bulky sidechains, C α -disubstituted derivatives (where the simplest derivative is Aib, H₂N-C(CH₃)₂-COOH), and cyclo amino acids, a simple derivative being amino-cyclopropylcarboxylic acid).

- Peptide bond surrogates, and examples include

- N-alkylation (see above, i.e. CO-NR)
- Reduced peptide bonds (CH₂-NH-)
- Peptoids (N-alkyl amino acids, NR-CH₂-CO)
- Thio-amides (CS-NH)
- Azapeptides (CO-NH-NR)
- Trans-alkene (RHC=C-)
- Retro-inverso (NH-CO)
- Urea surrogates (NH-CO-NHR)

5

- Peptide backbone length modulation

- i.e. $\beta^{2/3}$ - amino acids, (NH-CR-CH₂-CO, NH-CH₂-CHR-CO),

- Substitutions on the alpha-carbon on amino acids, which constrains backbone conformations, the simplest derivative being Aminoisobutyric acid (Aib).

It should be explicitly noted that some of these modifications may also serve to deliberately improve the potency of the peptide against the target, or, for example to identify potent substitutes for the oxidation-sensitive amino acids (Trp and Met). It should also be noted that the Bicycle lead Ac-06-34-18(TMB)-NH₂ already harbours two modifications that impart resistance to proteolytic degradation, these being N/C-terminal capping, and (bi)cyclisation.

15

20 **(B) Repertoires, sets and groups of polypeptide ligands**

(i) Construction of Libraries

Libraries intended for selection may be constructed using techniques known in the art, for example as set forth in WO2004/077062, or biological systems, including phage vector systems as described herein. Other vector systems are known in the art, and include other phage (for instance, phage lambda), bacterial plasmid expression vectors, eukaryotic cell-based expression vectors, including yeast vectors, and the like. For example, see WO2009098450 or Heinis, et al., *Nat Chem Biol* **2009**, 5 (7), 502-7.

25

Non-biological systems such as those set forth in WO2004/077062 are based on conventional chemical screening approaches. They are simple, but lack the power of biological systems since it is impossible, or at least impracticably onerous, to screen large libraries of peptide ligands. However, they are useful where, for instance, only a small
5 number of peptide ligands needs to be screened. Screening by such individual assays, however, may be time-consuming and the number of unique molecules that can be tested for binding to a specific target generally does not exceed 10^6 chemical entities.

In contrast, biological screening or selection methods generally allow the sampling of a much larger number of different molecules. Thus biological methods can be used in
10 application of the invention. In biological procedures, molecules are assayed in a single reaction vessel and the ones with favourable properties (i.e. binding) are physically separated from inactive molecules. Selection strategies are available that allow to generate and assay simultaneously more than 10^{13} individual compounds. Examples for powerful affinity selection techniques are phage display, ribosome display, mRNA
15 display, yeast display, bacterial display or RNA/DNA aptamer methods. These biological *in vitro* selection methods have in common that ligand repertoires are encoded by DNA or RNA. They allow the propagation and the identification of selected ligands by sequencing. Phage display technology has for example been used for the isolation of antibodies with very high binding affinities to virtually any target.

20 When using a biological system, once a vector system is chosen and one or more nucleic acid sequences encoding polypeptides of interest are cloned into the library vector, one may generate diversity within the cloned molecules by undertaking mutagenesis prior to expression; alternatively, the encoded proteins may be expressed and selected before mutagenesis and additional rounds of selection are performed.

25 Mutagenesis of nucleic acid sequences encoding structurally optimised polypeptides is carried out by standard molecular methods. Of particular use is the polymerase chain reaction, or PCR, (Mullis and Faloona (1987) Methods Enzymol., 155: 335, herein incorporated by reference). PCR, which uses multiple cycles of DNA replication catalysed by a thermostable, DNA-dependent DNA polymerase to amplify the target sequence of
30 interest, is well known in the art. The construction of various antibody libraries has been discussed in Winter et al. (1994) Ann. Rev. Immunology 12, 433-55, and references cited therein.

Alternatively, given the short chain lengths of the polypeptides according to the invention, the variants can be synthesised *de novo* and inserted into suitable expression vectors.

Peptide synthesis can be carried out by standard techniques known in the art, as described above. Automated peptide synthesisers are widely available, such as the Applied Biosystems ABI 433 (Applied Biosystems, Foster City, CA, USA)

(ii) Genetically encoded diversity

5 In one embodiment, the polypeptides of interest are genetically encoded. This offers the advantage of enhanced diversity together with ease of handling. An example of a genetically polypeptide library is a mRNA display library. Another example is a replicable genetic display package (rgdp) library such as a phage display library. In one
10 library.

Thus, in one embodiment the complex of the invention comprises a replicable genetic display package (rgdp) such as a phage particle. In these embodiments, the nucleic acid can be comprised by the phage genome. In these embodiments, the polypeptide can be comprised by the phage coat.

15 In some embodiments, the invention may be used to produce a genetically encoded combinatorial library of polypeptides which are generated by translating a number of nucleic acids into corresponding polypeptides and linking molecules of said molecular scaffold to said polypeptides.

The genetically encoded combinatorial library of polypeptides may be generated by
20 phage display, yeast display, ribosome display, bacterial display or mRNA display.

Techniques and methodology for performing phage display can be found in WO2009098450.

In one embodiment, screening may be performed by contacting a library, set or group of polypeptide ligands with a target and isolating one or more member(s) that bind to said
25 target.

In another embodiment, individual members of said library, set or group are contacted with a target in a screen and members of said library that bind to said target are identified.

In another embodiment, members of said library, set or group are simultaneously
30 contacted with a target and members that bind to said target are selected.

The target(s) may be a peptide, a protein, a polysaccharide, a lipid, a DNA or a RNA.

The target may be a receptor, a receptor ligand, an enzyme, a hormone or a cytokine.

The target may be a prokaryotic protein, a eukaryotic protein, or an archeal protein. More specifically the target ligand may be a mammalian protein or an insect protein or a
5 bacterial protein or a fungal protein or a viral protein.

The target ligand may be an enzyme, such as a protease.

It should be noted that the invention also embraces polypeptide ligands isolated from a screen according to the invention. In one embodiment the screening method(s) of the invention further comprise the step of: manufacturing a quantity of the polypeptide
10 isolated as capable of binding to said targets.

The invention also relates to peptide ligands having more than two loops. For example, tricyclic polypeptides joined to a molecular scaffold can be created by joining the N- and C- termini of a bicyclic polypeptide joined to a molecular scaffold according to the present invention. In this manner, the joined N and C termini create a third loop, making a
15 tricyclic polypeptide. This embodiment need not be carried out on phage, but can be carried out on a polypeptide-molecular scaffold conjugate as described herein. Joining the N- and C- termini is a matter of routine peptide chemistry. In case any guidance is needed, the C-terminus may be activated and/or the N- and C- termini may be extended for example to add a cysteine to each end and then join them by disulphide bonding.
20 Alternatively the joining may be accomplished by use of a linker region incorporated into the N/C termini. Alternatively the N and C termini may be joined by a conventional peptide bond. Alternatively any other suitable means for joining the N and C termini may be employed, for example N-C-cyclization could be done by standard techniques, for example as disclosed in Linde et al. Peptide Science 90, 671-682 (2008) "Structure-
25 activity relationship and metabolic stability studies of backbone cyclization and N-methylation of melanocortin peptides", or as in Hess et al. J. Med. Chem. 51, 1026-1034 (2008) "backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administered drug lead for treating obesity". One advantage of such tricyclic molecules is the avoidance of proteolytic degradation of the free ends, in particular by exoprotease
30 action. Another advantage of a tricyclic polypeptide of this nature is that the third loop may be utilised for generally applicable functions such as BSA binding, cell entry or transportation effects, tagging or any other such use. It will be noted that this third loop will not typically be available for selection (because it is not produced on the phage but

only on the polypeptide-molecular scaffold conjugate) and so its use for other such biological functions still advantageously leaves both loops 1 and 2 for selection/creation of specificity.

(iii) Phage purification

- 5 Any suitable means for purification of the phage may be used. Standard techniques may be applied in the present invention. For example, phage may be purified by filtration or by precipitation such as PEG precipitation; phage particles may be produced and purified by polyethylene-glycol (PEG) precipitation as described previously. Details can be found in WO2009098450.
- 10 In case further guidance is needed, reference is made to Jespers *et al* (Protein Engineering Design and Selection 2004 17(10):709-713. Selection of optical biosensors from chemisynthetic antibody libraries.) In one embodiment phage may be purified as taught therein. The text of this publication is specifically incorporated herein by reference for the method of phage purification; in particular reference is made to the materials and
- 15 methods section starting part way down the right-column at page 709 of Jespers *et al*.

Moreover, the phage may be purified as published by Marks *et al* J.Mol.Biol vol 222 pp581-597, which is specifically incorporated herein by reference for the particular description of how the phage production/purification is carried out.

(iv) Reaction chemistry

- 20 The present invention makes use of chemical conditions for the modification of polypeptides which advantageously retain the function and integrity of the genetically encoded element of the product. Specifically, when the genetically encoded element is a polypeptide displayed on the surface of a phage encoding it, the chemistry advantageously does not compromise the biological integrity of the phage. In general,
- 25 conditions are set out in WO2009098450.

(C) Use of polypeptide ligands according to the invention

- Polypeptide ligands selected according to the method of the present invention may be employed in *in vivo* therapeutic and prophylactic applications, *in vitro* and *in vivo* diagnostic applications, *in vitro* assay and reagent applications, and the like. Ligands
- 30 having selected levels of specificity are useful in applications which involve testing in non-human animals, where cross-reactivity is desirable, or in diagnostic applications, where

cross-reactivity with homologues or paralogues needs to be carefully controlled. In some applications, such as vaccine applications, the ability to elicit an immune response to predetermined ranges of antigens can be exploited to tailor a vaccine to specific diseases and pathogens.

- 5 Substantially pure peptide ligands of at least 90 to 95% homogeneity are preferred for administration to a mammal, and 98 to 99% or more homogeneity is most preferred for pharmaceutical uses, especially when the mammal is a human. Once purified, partially or to homogeneity as desired, the selected polypeptides may be used diagnostically or therapeutically (including extracorporeally) or in developing and performing assay
10 procedures, immunofluorescent stainings and the like (Lefkovite and Pernis, (1979 and 1981) Immunological Methods, Volumes I and II, Academic Press, NY).

The peptide ligands of the present invention will typically find use in preventing, suppressing or treating inflammatory states, allergic hypersensitivity, cancer, bacterial or viral infection, and autoimmune disorders (which include, but are not limited to, Type I
15 diabetes, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease and myasthenia gravis).

In the instant application, the term "prevention" involves administration of the protective composition prior to the induction of the disease. "Suppression" refers to administration of the composition after an inductive event, but prior to the clinical appearance of the
20 disease. "Treatment" involves administration of the protective composition after disease symptoms become manifest.

Animal model systems which can be used to screen the effectiveness of the peptide ligands in protecting against or treating the disease are available. The use of animal model systems is facilitated by the present invention, which allows the development of
25 polypeptide ligands which can cross react with human and animal targets, to allow the use of animal models.

Methods for the testing of systemic lupus erythematosus (SLE) in susceptible mice are known in the art (Knight et al. (1978) J Exp. Med., 147: 1653; Reinersten et al. (1978) New Eng. J : Med., 299: 515). Myasthenia Gravis (MG) is tested in SJL/J female mice by
30 inducing the disease with soluble AchR protein from another species (Lindstrom et al. (1988) Adv. Inzn7unol., 42: 233). Arthritis is induced in a susceptible strain of mice by injection of Type II collagen (Stuart et al. (1984) Ann. Rev. Immunol., 42: 233). A model by which adjuvant arthritis is induced in susceptible rats by injection of mycobacterial heat

shock protein has been described (Van Eden et al. (1988) *Nature*, 331: 171). Thyroiditis is induced in mice by administration of thyroglobulin as described (Maron et al. (1980) *J. Exp. Med.*, 152: 1115). Insulin dependent diabetes mellitus (IDDM) occurs naturally or can be induced in certain strains of mice such as those described by Kanasawa et al. (1984) *Diabetologia*, 27: 113. EAE in mouse and rat serves as a model for MS in human. In this model, the demyelinating disease is induced by administration of myelin basic protein (see Paterson (1986) *Textbook of Immunopathology*, Mischer et al., eds., Grune and Stratton, New York, pp. 179-213; McFarlin et al. (1973) *Science*, 179: 478: and Satoh et al. (1987) *J. Immunol.*, 138: 179).

Generally, the present peptide ligands will be utilised in purified form together with pharmacologically appropriate carriers. Typically, these carriers include aqueous or alcoholic/aqueous solutions, emulsions or suspensions, any including saline and/or buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride and lactated Ringer's. Suitable physiologically-acceptable adjuvants, if necessary to keep a polypeptide complex in suspension, may be chosen from thickeners such as carboxymethylcellulose, polyvinylpyrrolidone, gelatin and alginates.

Intravenous vehicles include fluid and nutrient replenishers and electrolyte replenishers, such as those based on Ringer's dextrose. Preservatives and other additives, such as antimicrobials, antioxidants, chelating agents and inert gases, may also be present (Mack (1982) *Remington's Pharmaceutical Sciences*, 16th Edition).

The peptide ligands of the present invention may be used as separately administered compositions or in conjunction with other agents. These can include antibodies, antibody fragments and various immunotherapeutic drugs, such as cyclosporine, methotrexate, adriamycin or cisplatinum, and immunotoxins. Pharmaceutical compositions can include "cocktails" of various cytotoxic or other agents in conjunction with the selected antibodies, receptors or binding proteins thereof of the present invention, or even combinations of selected polypeptides according to the present invention having different specificities, such as polypeptides selected using different target ligands, whether or not they are pooled prior to administration.

The route of administration of pharmaceutical compositions according to the invention may be any of those commonly known to those of ordinary skill in the art. For therapy, including without limitation immunotherapy, the selected antibodies, receptors or binding proteins thereof of the invention can be administered to any patient in accordance with

standard techniques. The administration can be by any appropriate mode, including parenterally, intravenously, intramuscularly, intraperitoneally, transdermally, via the pulmonary route, or also, appropriately, by direct infusion with a catheter. The dosage and frequency of administration will depend on the age, sex and condition of the patient, concurrent administration of other drugs, counterindications and other parameters to be taken into account by the clinician.

The peptide ligands of this invention can be lyophilised for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective and art-known lyophilisation and reconstitution techniques can be employed. It will be appreciated by those skilled in the art that lyophilisation and reconstitution can lead to varying degrees of activity loss and that use levels may have to be adjusted upward to compensate.

The compositions containing the present peptide ligands or a cocktail thereof can be administered for prophylactic and/or therapeutic treatments. In certain therapeutic applications, an adequate amount to accomplish at least partial inhibition, suppression, modulation, killing, or some other measurable parameter, of a population of selected cells is defined as a "therapeutically-effective dose". Amounts needed to achieve this dosage will depend upon the severity of the disease and the general state of the patient's own immune system, but generally range from 0.005 to 5.0 mg of selected peptide ligand per kilogram of body weight, with doses of 0.05 to 2.0 mg/kg/dose being more commonly used. For prophylactic applications, compositions containing the present peptide ligands or cocktails thereof may also be administered in similar or slightly lower dosages.

A composition containing a peptide ligand according to the present invention may be utilised in prophylactic and therapeutic settings to aid in the alteration, inactivation, killing or removal of a select target cell population in a mammal. In addition, the selected repertoires of polypeptides described herein may be used extracorporeally or in vitro selectively to kill, deplete or otherwise effectively remove a target cell population from a heterogeneous collection of cells. Blood from a mammal may be combined extracorporeally with the selected peptide ligands whereby the undesired cells are killed or otherwise removed from the blood for return to the mammal in accordance with standard techniques.

According to a further aspect of the invention, there is provided a method of preventing, suppressing or treating inflammatory states, allergic hypersensitivity, cancer, bacterial or viral infection, ophthalmic disorders and autoimmune disorders which comprises administering to a patient in need thereof a peptide ligand as defined herein.

Examples of suitable "ophthalmic disorders" (including exudative and/or inflammatory ophthalmic disorders, disorders related to impaired retinal vessel permeability and/or integrity, disorders related to retinal microvessel rupture leading to focal hemorrhages, back of the eye diseases, retinal diseases and front of the eye diseases) include but are not limited to: age related macular degeneration (ARMD), exudative macular degeneration (also known as "wet" or neovascular age-related macular degeneration (wet-AMD), macular oedema, aged disciform macular degeneration, cystoid macular oedema, palpebral oedema, retinal oedema, diabetic retinopathy, acute macular neuroretinopathy, central serous chorioretinopathy, chorioretinopathy, choroidal neovascularization, neovascular maculopathy, neovascular glaucoma, obstructive arterial and venous retinopathies (e.g. retinal venous occlusion or retinal arterial occlusion) , central retinal vein occlusion, disseminated intravascular coagulopathy, branch retinal vein occlusion, hypertensive fundus changes, ocular ischemic syndrome, retinal arterial microaneurysms, Coat's disease, parafoveal telangiectasis, hemi-retinal vein occlusion, papillophlebitis, central retinal artery occlusion, branch retinal artery occlusion, carotid artery disease (CAD) , frosted branch angitis, sickle cell retinopathy and other hemoglobinopathies, angioid streaks, macular oedema occurring as a result of aetiologies such as disease (e.g. diabetic macular oedema), eye injury or eye surgery; retinal ischemia or degeneration produced for example by injury, trauma or tumours, uveitis, iritis, retinal vasculitis, endophthalmitis, panophthalmitis, metastatic ophthalmia, choroiditis, retinal pigment epithelitis, conjunctivitis, cyclitis, scleritis, episcleritis, optic neuritis, retrobulbar optic neuritis, keratitis, blepharitis, exudative retinal detachment, corneal ulcer, conjunctival ulcer, chronic nummular keratitis, thygeson keratitis, progressive mooren's ulcer, an ocular inflammatory disease caused by bacterial or viral infection, and by an ophthalmic operation, an ocular inflammatory disease caused by a physical injury to the eye, a symptom caused by an ocular inflammatory disease including itching, flare, oedema and ulcer, erythema, erythema exsudativum multiforme, erythema nodosum, erythema annulare, scleroedema, dermatitis, angioneurotic oedema, laryngeal oedema, glottic oedema, subglottic laryngitis, bronchitis, rhinitis, pharyngitis, sinusitis, laryngitis or otitis media.

References herein to "back-of-eye diseases" include diseases affecting among other the retina, macular, fovea in the posterior region of the eye. Examples of suitable "back-of-eye diseases" include but are not limited to: macular oedema such as clinical macular oedema or angiographic cystoid macular oedema arising from various aetiologies such as diabetes, exudative macular degeneration and macular oedema arising from laser treatment of the retina, age-related macular degeneration, retinopathy of prematurity

(also known as retrolental fibroplasia), retinal ischemia and choroidal neovascularization, retinal diseases (diabetic retinopathy, diabetic retinal oedema, retinal detachment, senile macular degeneration due to sub-retinal neovascularization, myopic retinopathy); inflammatory diseases; uveitis associated with neoplasms such as retinoblastoma or pseudoglioma; neovascularization following vitrectomy; vascular diseases (retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, retinopathies resulting from carotid artery ischemia); and neovascularization of the optic nerve.

References herein to "front-of-eye diseases" refers to diseases affecting predominantly the tissues at the front-of-eye, such as the cornea, iris, ciliary body, conjunctiva etc. Examples of suitable "front-of-eye diseases" include but are not limited to: corneal neovascularization (due to inflammation, transplantation, developmental hypoplasia of the iris, corneal diseases or opacifications with an exudative or inflammatory component, neovascularization due to penetration of the eye or contusive ocular injury; chronic uveitis; anterior uveitis; inflammatory conditions resulting from surgeries such as LASIK, LASEK, refractive surgery, IOL implantation; irreversible corneal oedema as a complication of cataract surgery; oedema as a result of insult or trauma (physical, chemical, pharmacological, etc); inflammation; conjunctivitis (e.g. persistent allergic, giant papillary, seasonal intermittent allergic, perennial allergic, toxic, conjunctivitis caused by infection by bacteria, viruses or Chlamydia); keratoconjunctivitis (vernal, atopic, sicca) ; iridocyclitis; iritis; scleritis; episcleritis; infectious keratitis; superficial punctuate keratitis; keratoconus; posterior polymorphous dystrophy; Fuch's dystrophies (corneal and endothelial); aphakic and pseudophakic bullous keratopathy; corneal oedema; scleral disease; ocular cicatricial pemphigoid; pars planitis; Posner Schlossman syndrome; Behcet's disease; Vogt-Koyanagi-Harada syndrome; hypersensitivity reactions; ocular surface disorders; conjunctival oedema; toxoplasmosis chorioretinitis; inflammatory pseudotumor of the orbit; chemosis; conjunctival venous congestion; periorbital cellulitis; acute dacryocystitis; non-specific vasculitis; sarcoidosis; and cytomegalovirus infection.

Examples of suitable "disorders associated with excessive vascular permeability and/or edema in the eye", e.g. in the retina or vitreous, include, but are not limited to, age-related macular degeneration (AMD), retinal edema, retinal hemorrhage, vitreous hemorrhage, macular edema (ME), diabetic macular edema (DME), proliferative diabetic retinopathy (PDR) and non-proliferative diabetic retinopathy (DR), radiation retinopathy, telangiectasis, central serous retinopathy, and retinal vein occlusions. Retinal edema is the accumulation of fluid in the intraretinal space. DME is the result of retinal microvascular changes that occur in patients with diabetes. This compromise of the

blood-retinal barrier leads to the leakage of plasma constituents into the surrounding retina, resulting in retinal edema. Other disorders of the retina include retinal vein occlusions (e.g. branch or central vein occlusions), radiation retinopathy, sickle cell retinopathy, retinopathy of prematurity, Von Hippie Lindau disease, posterior uveitis, chronic retinal detachment, Irvine Gass Syndrome, Eals disease, retinitis, and/or choroiditis.

(D) Mutation of Polypeptides

The desired diversity is typically generated by varying the selected molecule at one or more positions. The positions to be changed are selected, such that libraries are constructed for each individual position in the loop sequences. Where appropriate, one or more positions may be omitted from the selection procedure, for instance if it becomes apparent that those positions are not available for mutation without loss of activity.

The variation can then be achieved either by randomisation, during which the resident amino acid is replaced by any amino acid or analogue thereof, natural or synthetic, producing a very large number of variants or by replacing the resident amino acid with one or more of a defined subset of amino acids, producing a more limited number of variants.

Various methods have been reported for introducing such diversity. Methods for mutating selected positions are also well known in the art and include the use of mismatched oligonucleotides or degenerate oligonucleotides, with or without the use of PCR. For example, several synthetic antibody libraries have been created by targeting mutations to the antigen binding loops. The same techniques could be used in the context of the present invention. For example, the H3 region of a human tetanus toxoid-binding Fab has been randomised to create a range of new binding specificities (Barbas et al. (1992) Proc. Natl. Acad. Sci. USA, 89: 4457). Random or semi-random H3 and L3 regions have been appended to germline V gene segments to produce large libraries with mutated framework regions (Hoogenboom- & Winter (1992) R Mol. Biol., 227: 381; Barbas et al. (1992) Proc. Natl. Acad. Sci. USA, 89: 4457; Nissim et al. (1994) EMBO J, 13: 692; Griffiths et al. (1994) EMBO J, 13: 3245; De Kruif et al. (1995) J. Mol. Biol., 248: 97). Such diversification has been extended to include some or all of the other antigen binding loops (Cramer et al. (1996) Nature Med., 2: 100; Riechmann et al. (1995) BiolTechnology, 13: 475; Morphosys, W097/08320, supra).

However, since the polypeptides used in the present invention are much smaller than antibodies, the preferred method is to synthesise mutant polypeptides de novo. Mutagenesis of structured polypeptides is described above, in connection with library construction.

- 5 The invention is further described below with reference to the following examples.

Examples

Materials and Methods

Cloning of phage libraries

Phage libraries were generated according to Heinis *et al.*, *Nat Chem Biol* **2009**, 5 (7), 502-7). In Heinis *et al.*, the genes encoding a semi-random peptide with the sequence Xaa-Cys-(Xaa)₃-Cys-(Xaa)₃-, the linker Gly-Gly-Ser-Gly and the two disulfide-free domains D1 and D2 (Kather, et al., *J Mol Biol* **2005**, 354 (3), 666-78) were cloned in the correct orientation into the phage vector fd0D12 to obtain 'library 3x3'. The genes encoding the peptide repertoire and the two gene 3 domains were step-wise created in two consecutive PCR reactions. First, the genes of D1 and D2 were PCR amplified with the two primer prepcr (5'-GGCGGTTCTGGCGCTGAAACTGTTGAAAGTAG-3') and sfi2fo (5'-GAAGCCATGGCCCCGAGGCCCGGACGGAGCATTGACAGG-3'; restriction site is underlined) using the vector fdg3p0ss21 (Kather, et al., *J Mol Biol* **2005**, 354 (3), 666-78) as a template. Second, the DNA encoding the random peptides was appended in a PCR reaction using the primer sficx3ba: 5'-TATGCGGCCAGCCGGCCATGGCANNKTGTNNKNNKNNKTGCNNKNNKNNKNNKTGTNNKG GCGGTTCTGGCGCTG-3' (restriction site is underlined), and sfi2fo. The ligation of 55 and 11 µg of *SfiI*-digested fd0D12 plasmid and PCR product yielded 5.6x10⁸ colonies on 10 20x20 cm chloramphenicol (30 µg/ml) 2YT plates. Colonies were scraped off the plates with 2YT media, supplemented with 15% glycerol and stored at -80°C. Construction of the libraries described herein employed the same technique to generate the semi-random peptide Pro-Ala-Met-Ala-Cys-(Xaa)₃-Cys-(Xaa)₃-Cys for a 3x3 library for example, and therefore replaced the sficx3ba primer sequence with: 5'-TATGCGGCCAGCCGGCCATGGCATGTNNKNNKNNKTGCNNKNNKNNKTGTGGCGGTTCTG GCGCTG-3'. Libraries with other loop lengths were generated following the same methodology.

Phage selections

Glycerol stocks of phage libraries were diluted to $OD_{600}=0.1$ in 500 ml 2YT/chloramphenicol (30 $\mu\text{g/ml}$) cultures and phage were produced at 30°C over night (15-16 hrs). Phage were purified and chemically modified as described in Heinis, et al., *Nat Chem Biol* **2009**, 5 (7), 502-7 Biotinylated hPK (3 μg) (IHPKA, from human plasma, Innovative Research, Novi, MI, USA) was incubated with 50 μl pre-washed magnetic streptavidin beads (Dyna, M-280 from Invitrogen, Paisley, UK) for 10 minutes at RT. Beads were washed 3 times prior to blocking with 0.5 ml washing buffer (10 mM Tris-Cl, pH 7.4, 150 mM NaCl, 10 mM MgCl_2 , 1mM CaCl_2) containing 1% BSA and 0.1% Tween 20 for 30 minutes at RT with rotation. Chemically modified phage (typically 10^{10} - 10^{11} t.u. dissolved in 2 ml washing buffer) were concomitantly blocked by addition of 1 ml washing buffer containing 3% BSA and 0.3% Tween 20. Blocked beads were then mixed with the blocked chemically modified phage and incubated for 30 minutes on a rotating wheel at RT. Beads were washed 8 times with washing buffer containing 0.1% Tween 20 and twice with washing buffer before incubation with 100 μl of 50 mM glycine, pH 2.2 for 5 minutes. Eluted phage were transferred to 50 μl of 1 M Tris-Cl, pH 8 for neutralization, incubated with 30 ml TG1 cells at $OD_{600}=0.4$ for 90 minutes at 37°C and the cells were plated on large 2YT/chloramphenicol plates. One or two additional rounds of panning were performed using the same procedures. In the second round of selection, neutravidin-coated magnetic beads were used to prevent the enrichment of streptavidin-specific peptides. The neutravidin beads were prepared by reacting 0.8 mg neutravidin (Pierce, Rockford, IL, USA) with 0.5 ml tosyl-activated magnetic beads (Dyna, M-280 from Invitrogen, Paisley, UK) according to the supplier's instructions.

Cloning and expression of human, monkey and rat PK

The catalytic domain of human, monkey and rat PK was expressed in mammalian cells as an inactive precursor having a pro-peptide connected N-terminally via a proTEV cleavage site to the catalytic domain. The expression vector was cloned and the protein expressed, activated and purified as described as follows. Synthetic genes coding for a PK signal sequence, a polyhistidine tag, a proTEV cleavage site, mature catalytic domain of PK and a stop codon were purchased from Geneart (Regensburg, Germany) (Supplementary materials). Plasmid DNA containing the synthetic genes for human, monkey (*Macaca mulatta*) and rat PK was prepared and the gene transferred into the pEXPR-IBA42 mammalian expression vector (IBA Biotechnology, Göttingen, Germany) using the restriction enzyme pair *XhoI* and *HindIII* (Fermentas, Vilnius, Latvia) and T4 DNA ligase (Fermentas). The ligated plasmids were transformed into XL-1 blue electrocompetent cells (Stratagene, Santa Clara, USA) and plated onto 2YT agar plates

containing ampicillin (10 µg/ml). DNA from the three expression vectors (termed mPK, rPK and hPK) was produced and the correct sequences confirmed by DNA sequencing (Macrogen, Seoul, South Korea).

The three orthologous plasma Kallikreins were expressed in mammalian cells as follows.

5 50 ml of suspension-adapted HEK-293 cells were grown in serum-free ExCell 293 medium (SAFC Biosciences, St. Louis, MO) in the presence of 4 mM glutamine and the histone deacetylase inhibitor valproic acid (3.75 mM) in an orbitally shaken 100 ml flask at 180 rpm in an ISF-4-W incubator (Kühner AG, Birsfelden, Switzerland) at 37 °C in the presence of 5% CO₂. The embryonic kidney (HEK-293) cells at high cell density (20 x 10⁶

10 cells/ml) (Backliwal, et al/. *Biotechnol Bioeng* **2008**, 99 (3), 721-7) were transfected with the three plasmids (300µg/ml) using linear polyethylenimine (PEI, Polysciences, Eppenheim, Germany). At the end of the 7-day production phase, cells were harvested by centrifugation at 2'500 rpm for 15 min at 4°C. Any additional cell debris was removed from the medium by filtration through 0.45 µm PES membranes (Filter-top 250 ml low

15 protein binding TPP). The polyhistidine-tagged protein was purified by Ni-affinity chromatography using Ni-NTA resin, washing buffer (500mM NaCl, 25mM Na₂HPO₄, pH7,4) and elution buffer (500 mM NaCl, 25 mM Na₂HPO₄, pH 7,4, 500 mM imidazole). The protein was partially activated with (50 units) proTEV (Promega, Madison, Wisconsin, USA) and additionally purified by Ni-affinity chromatography and gel filtration (PD10

20 column, 150 mM NaCl, 0,5 mM EDTA, 50 mM HEPES, pH 7).

Development of polypeptides with improved binding activity

Randomisation of individual positions

Library construction: In order to map the amino-acids in the Kallikrein binding bicyclic peptides a set of small libraries was constructed. For a bicycle comprised of 2 loops of 5

25 residues, 10 separate libraries were generated each with randomisation at a particular codon in the peptide sequence. Oligonucleotides were designed for each library in order to mutate the phage genome DNA by site-directed mutagenesis. The mutagenesis incorporated randomisation of the codon of interest (change to NNS), and removal of a unique ApaL1 restriction site from the template genome sequence. The mutagenesis

30 product was purified using QIAgen QIAquick PCR purification kit with elution into ultrapure water. Each library was used to separately transform TG1 *E coli* by electroporation with a BioRad Micropulser machine (Ec1 program) and 1mm BioRad cuvette. After 1 hour recovery at 37C in 1ml SOC media, the library transformants were grown overnight in 25ml 2TY broth containing antibiotic to selectively grow library

transformants only. The bacteria were harvested by centrifugation and the library phage DNA was purified from the *E coli* using a QIAgen Plasmid Plus Midi kit and eluted in distilled water. The purified DNA was digested with ApaL1 for 2 hours in New England Biolabs buffer 4 to remove the parent material. After digestion, the DNA was repurified using QIAgen PCR purification kit (as above) and used to transform TG1 (electroporation; as described above). Following the 1 hour recovery in SOC, transformants were plated on LB-agar plates containing selective antibiotic and colonies allowed to grow overnight at 37C.

Assay of binding of individual clones: Library transformant colonies were picked at random and grown as individual cultures in 2TY broth containing selective antibiotic. The picked colonies were DNA-sequenced using a QIAgen PyroMark Q96 DNA sequencer to reveal the amino-acid substitution present in each clone. Where isolated, a clone of each unique substitution was assayed for human plasma Kallikrein binding as follows. The phage-containing supernatant was harvested from the culture and phage were cyclised with tris bromomethyl benzene(TBMB) based on the methods of Heinis *et al* (Nature Chemical Biology vol. 5 pp 502-507 (2009)). The purified phage from this process were assayed for binding to biotinylated human plasma Kallikrein using a homogeneous plate-based binding assay; assay read-out measured on a BMG Labtech Pherastar FS plate reader. The quantitative binding data from triplicate assay samples was averaged (mean) and expressed as signal:background (where background was a sample assayed with no target material). The signal:background was expressed as a % of the parallel parent sample. Error bars denote standard deviation of the mean. Assays shown are representative of at least 2 independent experiments. The assay data was correlated with the peptide sequences. Substitutions marked in grey were not tested (a clone was not isolated from the random library sampling). A sample of a non-binding (arbitrary) bicycle was assayed in parallel to illustrate the assay baseline.

Randomisation of peptide domains

Library construction: Small phage libraries were generated according to the methods of Heinis *et al* as described in 'Cloning of phage libraries' above. The sficx3ba primer was modified such that the bicycle-encoding portion was based on a parent 5x5 bicycle (5x5: two 5-residue loops) DNA sequence with only 4-6 codons randomized to NNS. The randomized codons were those encoding the peptide domain/motif of interest.

Assay of binding of individual clones: Library transformant colonies, or selection output colonies, were picked and grown as individual cultures in 2TY broth containing selective

antibiotic. The picked colonies were DNA-sequenced using a QIAGEN PyroMark Q96 DNA sequencer to reveal the amino-acid substitution present in each clone, and were assayed for human plasma Kallikrein binding as follows. The phage-containing supernatant was harvested from the culture and phage were cyclised with tris bromomethyl benzene (TBMB) based on the methods of Heinis *et al* (Nature Chemical Biology vol. 5 pp 502-507 (2009)). The purified phage from this process were assayed for binding to biotinylated human plasma Kallikrein using a homogeneous plate-based binding assay; assay read-out measured on a BMG Labtech Pherastar FS plate reader. The quantitative binding data from duplicate assay samples was averaged (mean) and expressed as signal:background. Assay data shown is representative of at least 2 independent experiments. The assay data was correlated with the peptide sequences.

Synthesis and purification of bicyclic peptides

Peptide sequences are shown in Tables 4 to 6. The core peptide sequences were Ac-C₁S₁W₂P₃A₄R₅C₂L₆H₇Q₈D₉L₁₀C₃-NH₂ (denoted as Ac-(06-34-18)(TMB)-NH₂) and Ac-C₁S₁F₂P₃Y₄R₅C₂L₆H₇Q₈D₉L₁₀C₃-NH₂ (denoted as Ac-(06-34-18)(TMB)-NH₂ Phe² Tyr⁴).

Peptide synthesis was based on Fmoc chemistry, using a Symphony peptide synthesiser manufactured by Peptide Instruments. Standard Fmoc-amino acids were employed (Sigma, Merck), with the following side chain protecting groups: Arg(Pbf); Asn(Trt); Asp(OtBu); Cys(Trt); Glu(OtBu); Gln(Trt); His(Trt); Lys(Boc); Ser(tBu); Thr(tBu); Trp(Boc), Tyr(tBu) (Sigma). The coupling reagent was HCTU (Pepceuticals), diisopropylethylamine (DIPEA, Sigma) was employed as a base, and deprotection was achieved with 20% piperidine in DMF (AGTC). Syntheses were performed at 100 umole scale using 0.37 mmole/gr Fmoc-Rink amide AM resin (AGTC), Fmoc-amino acids were utilised at a four-fold excess, and base was at a four-fold excess with respect to the amino acids. Amino acids were dissolved at 0.2 M in DMF, HCTU at 0.4 M in DMF, and DIPEA at 1.6 M in N-methylpyrrolidone (Alfa Aesar). Coupling times were generally 30 minutes, and deprotection times 2 x 2.5 minutes. Fmoc-N-methylglycine (Fmoc-Sar-OH, Merck) was coupled for 1 hr, and deprotection and coupling times for the following residue were 20 min and 1 hr, respectively. After synthesis, the resin was washed with dichloromethane, and dried. Cleavage of side-chain protecting groups and from the support was effected using 10 mL of 95:2.5:2.5:2.5 v/v/v/w TFA/H₂O/iPr₃SiH/dithiothreitol for 3 hours. Following cleavage, the spent resin was removed by filtration, and the filtrate was added to 35 mL of diethylether that had been cooled at -80 deg C. Peptide pellet was centrifuged, the etheric supernatant discarded, and the peptide pellet washed with cold

ether two more times. Peptides were then resolubilised in 5-10 mL acetonitrile-water and lyophilised. A small sample was removed for analysis of purity of the crude product by mass spectrometry (MALDI-TOF, Voyager DE from Applied Biosystems). Following lyophilisation, peptide powders were taken up in 10 mL 6 M guanidinium hydrochloride in H₂O, supplemented with 0.5 mL of 1 M dithiothreitol, and loaded onto a C8 Luna preparative HPLC column (Phenomenex). Solvents (H₂O, acetonitrile) were acidified with 0.1 % heptafluorobutyric acid. The gradient ranged from 30-70 % acetonitrile in 15 minutes, at a flowrate of 15/20 mL /min, using a Gilson preparative HPLC system. Fractions containing pure linear peptide material (as identified by MALDI) were combined, and modified with trisbromomethylbenzene (TBMB, Sigma). For this, linear peptide was diluted with H₂O up to ~35 mL, ~500 uL of 100 mM TBMB in acetonitrile was added, and the reaction was initiated with 5 mL of 1 M NH₄HCO₃ in H₂O (pH 8). The reaction was allowed to proceed for ~30 -60 min at RT, and lyophilised once the reaction had completed (judged by MALDI). Following lyophilisation, the modified peptide was purified as above, while replacing the Luna C8 with a Gemini C18 column (Phenomenex), and changing the acid to 0.1% trifluoroacetic acid. Pure fractions containing the correct TMB-modified material were pooled, lyophilised and kept at -20 deg C for storage.

Non-natural amino acids were acquired from the sources set forth in Table 7.

Bulky or hindered amino acids (NMe-Ser, NMe-Trp, NorHar, 4PhenylPro, Agb, Agp, NMe-Arg, Pen, Tic, Aib, Hyp, NMe-Ala, NMe-Cys, 4,4-BPAI, 3,3-DPA, Dpg, 1NAI, 2NAI, Aze, 4BenzylPro, Ind) were usually coupled for 1 hours (20 min deprotection), and 6 hrs for the residue that followed (20 min deprotection). HCTU was used as a coupling reagent as before. Scale was usually at 50 umole.

Synthesis of peptoids, reduced amide bonds and α -N-methylated peptides

Peptoids (i.e. N-His₇) were synthesised according to the scheme developed by Zuckermann et al. (Ronald N. Zuckermann, Janice M. Kerr, Stephen B. H. Kent, Walter H. Moos, Efficient method for the preparation of peptoids [oligo(N-substituted glycines)] by submonomer solid-phase synthesis Journal of the American Chemical Society, (1992), 114(26), 10646-10647).

Reduced amide pseudo peptide bonds were synthesised according to the scheme in Sasaki Y, Coy DH., Solid phase synthesis of peptides containing the CH₂NH peptide bond isostere, Peptides. 1987 Jan-Feb;8(1):119-21.

N-methylated peptides (NMe-His, NMe-Gln) were synthesised using a modified form of the Mitsunobu reaction, according to a scheme described in Nature Protocols, “Synthesis of N-methylated cyclic peptides”, by Chatterjee et al, 7(3) 2012, pp432. All other N-methylated amino acids (NMe-Leu, NMe-Asp) were obtained as Fmoc precursors from commercial sources.

Enzyme assays

Functional enzyme assays were conducted in 10mM Tris HCl, 150mM NaCl, 10mM MgCl₂, 1mM CaCl₂ and 1mg/mL BSA (all Sigma UK) pH7.4 at 25°C in solid black 96 well plates. Briefly 26.5pM human plasma Kallikrein (purchased from Stratech, UK) or 500pM rat plasma Kallikrein (expressed and purified in house) were incubated in the absence or presence of increasing concentrations of test peptide for 15 minutes before addition of the fluorogenic substrate Z-PheArg-AMC (Enzo Lifesciences UK) to a final assay concentration of 100µM in 4% DMSO. Release of AMC was measured using a Pherastar FS (BMG Labtech), excitation 360nm, emission 460nm. The rate of the linear phase of the reaction, typically 5 to 45 minutes, was calculated in MARS data analysis software (BMG labtech). The rate was then used to calculate the IC₅₀ and K_i in Prism (GraphPad). A four parameter inhibition non-linear regression equation was used to calculate the IC₅₀. The One site – fit K_i equation used to calculate the K_i, constraining the K_i to the K_m for the substrate which is 150µM. All K_i/IC₅₀ values are the mean of at least two independent experiments, and at least three for peptides with K_i values lower than 1 nM.

Peptides were dissolved as the TFA-salts in their powder form, and stock solutions were usually prepared in water. All solutions were centrifuged and filtered (20 µm syringe filters) prior absorption measurement at 280 nm. Extinction coefficients were calculated based on the Trp/Tyr content of the peptide, and that of TMB (the TMB core, when contained in a peptide, has an ϵ of $\sim 300 \text{ M}^{-1}\text{cm}^{-1}$). For peptides containing non-natural amino acids with suspected chromophoric properties (i.e. NorHar, 4PhenylPro, 3Pal, 4Pal, Tic, 4GuanPhe, 4,4-BPAI, 3,3-DPA, 1NAI, 2NAI, 4BenzylPro, Ind) concentrations were determined by weighing the powder and dissolving the peptide in a defined quantity of water. These were prepared independently, twice, for peptides with a K_i to Kallikrein at 1 nM or less.

Plasma stability profiling

Three methods were employed to assess the stability of bicycles (peptides conjugated to molecular scaffolds) in plasma.

Method #1:

A rapid plasma stability profiling assay was developed that employed mass spectrometric detection (MALDI-TOF, Voyager DE, Applied Biosystems) of the parent mass, until the time when the parent peptide mass was no longer observable. Specifically, 200 μ M of peptide was incubated in the presence of 35% rat or human plasma (Sera labs, using citrate as anticoagulant) at 37 deg C, which was supplemented with 1 x PBS (derived from a 10 xPBS Stock, Sigma). At various time points (i.e. t = 0, 3, 24 hrs, henceafter daily up to 10 days), 2 μ L of sample was added to 18 μ L of 30 mM ammonium bicarbonate in a 1:1 mixture of acetonitrile:H₂O. Samples were frozen at -80 deg C until the time of analysis. For mass spectrometric analysis that determines the approximate detection window of the peptide, the acetonitrile:H₂O-diluted sample of a given time point was spotted directly (0.7 μ L) onto the MALDI plate. Matrix (alpha-cyanocinnamic acid, Sigma, prepared as a saturated solution in 1:1 acetonitrile:water containing 0.1% trifluoroacetic acid) was layered over the sample (1 μ L). At a similar laser intensity setting on the MALDI TOF, the time could then be determined until parent peptide was no longer detectable. It should be noted that this is a qualitative assay serves to detect relative changes in plasma stability.

Method #2:

To obtain stability data more rapidly, peptides were also assessed in 95% plasma. Here, PBS was omitted, and a 1 mM peptide stock (in DMSO) was directly diluted into plasma (i.e. 2.5 μ L stock into 47.5 μ L plasma), giving a final concentration of 50 μ M. 5 μ L samples were taken at appropriate time points and frozen at -80 deg C. For analysis, the samples were defrosted, mixed with 15 μ L of 1:1 acetonitrile:methanol, and centrifuged at 13k for 5 min. 5 μ L of the peptide-containing supernatant was aspirated and mixed with 30 mM ammonium bicarbonate in a 1:1 mixture of acetonitrile:H₂O. 1 μ L of this was then spotted on the MALDI plate and analysed as described above. As above, it should be noted that this is a qualitative assay serves to detect relative changes in plasma stability.

Method #3:

To obtain plasma stability quantitatively, peptide stock solutions (1 mM in DMSO) were shipped to Biofocus, UK, who performed the analysis. Peptides were diluted to 100 uM with water, and diluted 1:20 in plasma (5 uM final concentration, with the plasma at 95%), sampled as appropriate, precipitated as above, and quantified using a Waters Xevo TQ-MS.

Example 1: Identification of preferred residues for binding activity

From the examples of 5x5 peptides shown in Table 4 it is possible to identify amino acids that are conserved between peptides with binding activity. To determine which residues were preferred for binding activity, representatives from two of the identified families of peptides were studied further. These were peptides 06-34, which comprises a CXWPARC motif in the first loop of the bicycle, and peptide 06-56, which comprises a CGGxxNCR motif across both loops of the bicycle. For each peptide sequence, a set of 10 phage libraries was created in which 9 of the loop residues were kept constant and the other residue was randomised so that any amino-acid could be expressed in the library at that position. (See '*Randomisation of individual positions – Library construction*' in Methods above.) For each library a set of 20 randomly selected phage clones were screened for binding to human Kallikrein in a phage binding assay to identify the critical residues for target binding. (See '*Randomisation of individual positions – Assay of binding of individual clones*' in Methods above.) The data from this experiment are shown in Figures 4 - 6.

For peptide 06-34 (Figure 4), it is clear that Arg1 of the bicycle can be replaced with a variety of different amino-acids and binding to human plasma Kallikrein is retained or enhanced. By contrast, replacement of residues 2, 3, 4, 5 (Trp2, Pro3, Ala4, Arg5) by most amino acids greatly reduced the signal seen in an assay that was set up with a stringent cut-off for high affinity binders. Val6 can be replaced by many different amino-acids and binding activity is retained or enhanced. Replacement of other residues in the second loop indicated that only Leu10 could be replaced by a variety of different amino-acids whilst retaining activity. Positions 7, 8, and 9 have limited capacity for substitution and no substitutions were identified that enhanced binding.

For peptide 06-56 (Figures 5 and 6) it is clear that glycines at position 1 and 2 are the greatly preferred residues for binding to plasma Kallikrein as are arginine, tryptophan and threonine at positions 6, 8, and 9. Glutamine at position 4 and threonine at position 10

can be replaced by a variety of residues whilst retaining good binding activity. The three remaining residues – proline at position 1, asparagine at position 5 and threonine at position 7 have limited capacity for substitution.

Analysis of amino-acid replacements

5 From the preceding analysis it is apparent that for 06-34, position one and position six can be replaced by a variety of amino-acids and still retain binding activity equal or greater than that of the parent peptide. To evaluate whether these observations would hold with isolated synthetic peptides, a set of peptides was designed according to the findings in Figure 4, where Arg1 was replaced by a serine, and where Val6 was
10 substituted by either threonine, methionine or leucine. Peptides employing the various combinations of these substitutions were also synthesised. These substitutions produced a greater binding signal in the assay (Table 5).

All of the variant synthetic peptides had approximately equivalent or enhanced activity against human plasma Kallikrein in enzyme inhibition assays compared to the 06-34
15 parent peptide, indicating that this type of analysis could be used to fine-tune target binding affinities, and suggesting a route to identifying lead peptide candidates of very high potencies.

The peptides were also tested against rat plasma Kallikrein in isolated enzyme assays. Substitution of Arg1 to Ser1 had a marginal impact on activity against rat Kallikrein,
20 whereas substitutions of Val6 to threonine, methionine or leucine generated peptides with markedly increased potency against rat plasma Kallikrein. Activity to human Kallikrein was fully retained. Thus, by determining positions amenable to substitutions, peptides with desirable properties, such as target orthologue cross-reactivity, can be identified.

To demonstrate the possibility of replacing these two positions with non-natural amino
25 acids so as to have the capacity to introduce functionalities or properties that are not present in the parent peptide, Arg1 and Val6 in 06-34-03 were replaced with either alanine or N-methylglycine (sarcosine), or with N-methyl serine on position 1, and evaluated for binding. Remarkably, as shown in Table 6, positions 1/6 are amenable to removal of the side chain altogether, as the R1A/V6A (06-34-03 Ala1,6) peptides retained
30 full potency compared to the parent. Replacement of residues 1,6 with N-methylglycine (06-34-03 NMeGly1,6) caused a reduction in potency, however the binding affinity remained in the low nanomolar range. Introduction of an N-methylserine at position 1 causes a ten-fold loss in potency, but binding remains in the picomolar range. Thus,

certain positions in the bicycle can be identified that allow changes in the peptide backbone structure or side chains, which could allow for deliberate enhancement of protease stability, enhanced solubility, reduced aggregation potential, and introduction of orthologous functional groups.

5 **Example 2: Detailed analysis of WPAR domain.**

The WPAR motif identified from Example 1 was analysed in the context of the 06-34-03 peptide, in order to identify alternatives or improvements to the WPAR motif. A library was constructed where positions 1, 6, 7, 8, 9 & 10 of 06-34-03 were fixed and positions 2, 3, 4 & 5 were randomised (see '*Randomisation of peptide domains – Library construction*' in Methods above). Selections against human plasma Kallikrein were performed at a variety of stringencies (see '*Phage selections*' in Methods above). All output sequences were identified and analysed for target binding (see '*Randomisation of peptide domains – Assay of binding of individual clones*' in Methods above). Table 17 lists each unique sequence, its relative abundance in the selection output (frequency), and a rank number according to target binding strength.

Table 17 shows that WPAR motif confers the best binding to human plasma Kallikrein, although other Kallikrein binding sequences are retrieved from selections in high abundance. These include, but are not restricted to: WPSR, WPAR, WSAR, WPFR, WPYR, FPFR, & FPFR. The most effective and abundant motifs at positions 2, 3, 4 & 5 can be summarised as: $^W/_F P \times ^K/_R$

Table 18(A) shows that WPAR & WPSR were most abundant in the more stringent selection outputs; FPFR & FPYR were abundant in the lower stringency selection outputs. This would indicate that WPAR-like sequences are stronger binders than FPFR-like sequences. Analysis of each motif (within the 06-34-03 context) in the target binding assay (Table 18(B)), reveals that WPAR at positions 2, 3, 4 & 5 of the 06-34-03 sequence is the optimal sequence for Kallikrein binding.

Example 3: Optimisation of the sequence outside the WPAR pharmacophore

The WPAR motif and its variants have been studied within the context of peptide 06-34-03. Figure 1 demonstrates that some positions outside of the WPAR motif can maintain Kallikrein binding when substituted for other residues. In order to study the non-WPAR determinants of Kallikrein binding, a phage library was generated with a fixed-WPAR

sequence and all other positions randomised (CxWPARCxxxxxC) as described in 'Randomisation of peptide domains – Library construction' in Methods above.

80 random library members were isolated directly from the library pool (no selection) and assayed for binding to Kallikrein at both high and low stringency (see 'Randomisation of peptide domains – Assay of binding of individual clones' in Methods above). These library members, which contain random sequences outside the WPAR, showed little or no binding to human plasma Kallikrein (data not shown), indicating that the presence of a WPAR motif alone is not sufficient to retain measureable Kallikrein binding: the rest of the bicycle sequence must also contribute or influence the interaction.

Selections against human plasma Kallikrein were performed with this library in order to study the non-WPAR determinants of Kallikrein binding, and to isolate the optimal WPAR-containing peptide sequence. Over 150 selection output sequences were isolated and screened for binding to human plasma Kallikrein (as described in Methods above). The sequences were ranked in order of Kallikrein binding and the top 50 sequences were aligned in Table 19. Table 19 shows that the residue at position 1 does not affect Kallikrein binding, but a strong consensus for Histidine is seen at position 7 (which supports findings in Example 1 above). The peptide 06-34-03 – derived from the work in Example 1 – is one of the best sequences. The composition of the second loop shows clear trends which confer strong Kallikrein binding when with a WPAR motif.

The best WPAR-containing binders to human plasma Kallikrein have the trend:

C X W P A R C ^T_L H ^Q_T D L C

H7, D9 and L10 are heavily conserved in WPAR-containing Kallikrein binding sequences.

Two motifs in within the second bicycle loop (positions 6-10) were identified:

1. **C X W P A R C T H ^Q_T D L C** (positions 6, 7 & 10: "THxxL")
2. **C X W P A R C ^T_L H ^Q_T D L C** (positions 7, 8, & 10: "xHxDL")

Over 120 identified human plasma Kallikrein binders (selection output sequences) were grouped 2 different ways, according to their derivation from motifs "THxxL" or "xHxDL". For all groups, the average Kallikrein binding assay signal for output sequences was noted as a measure of Kallikrein binding for a given group (Table 20).

The Kallikrein binding assay data shown in Table 20 demonstrates that 'THxxL' and 'xHxDL' motifs result in the best Kallikrein binding when in a bicyclic peptide with a WPAR motif. The combination of the 2 motifs, 'THxDL', gives the highest binding to human plasma Kallikrein and includes the 'THQDL' second loop sequence of the 06-34-03 peptide.

Example 4: Systematic analysis of plasma stability.

For a Kallikrein-inhibiting bicycle, it is pertinent to obtain an adequate protease stability profile, such that it has a low protease-driven clearance in plasma or other relevant environments. In a rapid comparative plasma stability assay (methods section, method #1) that observed the progressive disappearance of parent peptide in rat plasma, it was found that the N-terminal alanine (which is present at the time of selections and was originally included in synthetic peptides of lead sequences) is rapidly removed across all bicycle sequences tested by both rat and human plasma. This degradation was avoided by synthesising a lead candidate lacking both N- and C-terminal alanines. To remove potential recognition points for amino- and carboxypeptidases, the free amino-terminus that now resides on Cys 1 of the lead candidate is capped with acetic anhydride during peptide synthesis, leading to a molecule that is N-terminally acetylated. In an equal measure, the C-terminal cysteine is synthesised as the amide so as to remove a potential recognition point for carboxypeptidases. Thus, bicyclic lead candidates have the following generic sequence: Ac-**C**₁AA₁AA₂AA_n**C**₂AA_{n+1}AA_{n+2}AA_{n+3}**C**₃(TMB)-NH₂, where "Ac" refers to N-terminal acetylation, "-NH₂" refers to C-terminal amidation, where "C₁, C₂, C₃" refers to the first, second and third cysteine in the sequence, where "AA₁" to "AA_n" refers to the position of the amino acid (whose nature "AA" is defined by the selections described above), and where "(TMB)" indicates that the peptide sequence has been cyclised with TBMB or any other suitable reactive scaffold.

Due to the high affinity of Ac-06-34-18(TMB)-NH₂ to both human (K_i = 0.17 nM) and rat Kallikrein (IC₅₀ = 1.7 nM), we chose this Bicycle for lead development (Figure 9, Table 1, Table 5). Using the same rapid plasma stability profiling assay described above, Ac-06-34-18(TMB)-NH₂ had an observability window of about 2 days (methods section, method #1), which equates to a rat plasma half-life of ~ 2 hrs (as determined quantitatively by LC/MS, see below, table 23, method #3).

In an effort to identify the proteolytic recognition site(s) in Ac-06-34-18(TMB)-NH₂, the peptide was sampled in 35% rat plasma over time (method #1), and each sample was analysed for the progressive appearance of peptide fragments using MALDI-TOF mass

spectrometry. The parent mass of Ac-06-34-18(TMB)-NH₂ is 1687 Da. Over time (Figure 7, 8), fragments appear of the masses 1548.6 (M1), 1194.5 (M2), and 1107.2 (M3). From the sequence of Ac-06-34-18(TMB)-NH₂ (Ac-C₁S₁W₂P₃A₄R₅C₂L₆H₇Q₈D₉L₁₀C₃-NH₂), it can be calculated that the peak of M1 corresponds to Ac-06-34-18(TMB)-NH₂ lacking Arg5 (-R5). This appears to be the initial proteolytic event, which is followed by removal of the 4-amino acid segment WPAR in Ac-06-34-18(TMB)-NH₂ (M2, -WPAR), and finally the entire first loop of Ac-06-34-18(TMB)-NH₂ is excised (M3, -SWPAR) (Figure 8). From this data, it is evident that Arg5 of Ac-06-34-18(TMB)-NH₂ is the main rat plasma protease recognition site that is responsible the degradation of the Bicycle.

10 Alanine substitutions and scrambling of first loop:

Having identified Arg5 in constituting the recognition site for rat plasma proteases, a campaign of chemical synthesis of Ac-06-34-18(TMB)-NH₂ derivatives was undertaken with the aim of identifying candidates with higher plasma proteolytic stability. Crucially, such modifications should not affect the potency against human or rat Kallikrein. An initial exploration regarding the role of the WPAR sequence/pharmacophore (Figure 9, 10) was performed by replacing W₂P₃ with A₂A₃ or A₂Q₃ and by scrambling parts or the entire first loop of the bicycle. Table 8 below shows the sequences and the respective affinities against Kallikrein.

From these data it is clear that concomitant removal of W₂P₃ dramatically reduces binding to Kallikrein by a factor of ~100000, effectively rendering the molecule pharmacologically inert. The importance of the correct *sequence* of the amino acids is underlined by the four scrambled peptides (Scram 1-4), as all of them display a substantial reduction in affinity towards Kallikrein (Figure 10). Curiously, all peptides have a roughly identical rat plasma stability profile (between 1 to 2 days, method #1), indicating that plasma protease recognition relies on the *presence* of the arginine (producing a degradation pattern similar to Figure 7), and not on its *position* within the sequence.

Next, five derivatives of Ac-06-34-18(TMB)-NH₂ were generated where W₂, P₃, A₄, R₅, and C₂ were replaced with their respective D-enantiomeric counterparts (Table 9).

From the data it is clear that D-amino acid replacement of A₄, R₅, and C₂ increase peptide stability towards plasma proteases. As Arg5 excision by rat plasma proteases appears to be the first event in peptide degradation, the initial hydrolysis of peptide bonds will occur on the N- and/or C-terminal side of Arg5. It is plausible that replacing the amino acids to either side of Arg5 with their D-enantiomers blocks adjacent peptide bond hydrolysis

through steric hindrance. Indeed, this is an effect that has been observed previously (Tugyi *et al* (2005) PNAS, 102(2), 413–418).

5 The detrimental effect of D-amino acid substitution on affinities to Kallikrein is striking in all cases; losses in potencies range from 300- (D-Arg5) to 45000-fold (D-Trp2). This underlines the importance of the correct three-dimensional display of these sidechains to the Kallikrein bicycle binding pocket. Equally striking is the effect of D-Ala4: here, changing the orientation of a single methyl group (being the Ala side chain) reduces the affinity 7000-fold.

N-methylations:

10 Next, residues in the first loop were systematically replaced with their N-methyl counterparts. N-methylation serves as a straightforward protection of the peptide bond itself; however, due to the absence of the amide hydrogen, addition of steric bulk (the methyl group) and changes in preferred torsional angles, losses in potencies are expected.

15 Table 10 summarises the data.

N-methylation of amino acids in loop 1 displays an altogether less drastic detrimental effect on potency. In particular, N-methylation of Arg5 still yields a single digit nanomolar binder (20-fold reduction in affinity compared to wildtype peptide), and its rat plasma stability exceeds the assay time (fragmentation of the peptide in the MS was not observable), making this an attractive improved lead candidate. As with the D-amino acid substitutions, N-methylation of residues adjacent to Arg5 imparts enhanced stability to the peptide, presumably through steric interference affecting protease-catalysed hydrolysis of peptide bonds N and/or C-terminal to Arg5. Of note, Ser1 can be N-methylated without a significant loss in potency, indicating that the integrity of the peptide backbone in this position is not essential for binding.

Arginine substitutions:

Given the importance of Arg5 in recognition by rat plasma proteases, a set of arginine analogues were tested in the Ac-06-34-18(TMB)-NH₂ lead. The chemical structures are shown in Figure 11, and the potency versus stability data is shown in Table 11.

30 Strikingly, all arginine analogues increase the stability of the peptide beyond the assay window time, confirming the importance of the integrity of Arg5 in plasma protease

recognition. Increasing (HomoArg) or decreasing the length of the side chain (Agb, Agp) both decrease affinity, however the HomoArg analogue still yields a very good binder ($K_i = 2.1 \text{ nM}$), with enhanced stability. Lengthening the amino acid backbone by one methylene group in Arg5 (a so-called beta-amino acid) while retaining the same side chain (β -homoArg5) also yields a binder with enhanced stability, however at the price of a more significant reduction in affinity ($K_i = 8.2 \text{ nM}$). Replacing the aliphatic part of the Arg side chain with a phenyl ring yields a resonance stabilised, bulkier and rigidified guanidyl-containing side chain (4GuanPhe). Of all the Arg analogues tested, 4GuanPhe had the greatest affinity (2-fold reduction compared to wildtype), at an enhanced plasma stability. Interestingly, the guanidylphenyl group is structurally close to the known small molecule Kallikrein inhibitor benzamidine (Stürzebecher et al (1994), *Novel plasma Kallikrein inhibitors of the benzamidine type*. Braz J Med Biol Res. 27(8):1929-34; Tang et al (2005), *Expression, crystallization, and three-dimensional structure of the catalytic domain of human plasma Kallikrein*. J.Biol.Chem. 280: 41077-89). Furthermore, derivatised Phenylguanidines have been employed as selective inhibitors of another serine protease, uPA (Sperl et al, *(4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase* (2000) Proc Natl Acad Sci U S A. 97(10):5113-8.). Thus, Ac-06-34-18(TMB)-NH₂ containing 4GuanPhe5 can be viewed as a small molecule inhibitor, whose selectivity is imparted by the surrounding Bicyclic peptide. This can comprise a principle for other bicycle-based inhibitors, where a known small molecule inhibitor of low selectivity is “grafted” onto a Bicycle in the correct position, leading to a molecule of superior potency and selectivity.

Modification of the Arg guanidyl group itself, either by methylation (SDMA, NDMA), removal of the positive charge (Cit, where the guanidyl group is replaced by the isosteric but uncharged urea group) or deletion of the Arg altogether (Δ Arg) has strongly detrimental effects on Kallikrein binding potency. Thus, the integrity and presence of the guanidyl group is crucial, while the nature of the sidechain connecting to the guanidyl group or backbone at Arg5 is not. Of note, Arg5 may also be replaced by lysine, however again at reduced affinities (see WPAK peptide).

In summary, data this far indicates that Ac-06-34-18(TMB)-NH₂ employing either HomoArg, NMeArg or 4GuanPhe as arginine replacements could constitute plasma stability enhanced candidates with high affinities.

Example 5: Improving the potency of a lead candidate through non-natural modifications and combination with plasma-stability enhancing modifications.

Improving the potency of a given bicyclic candidate can be feasibly achieved through several mechanisms. These have been partially addressed in Example 4, and can be
 5 rewritten as follows:

1. Incorporating hydrophobic moieties that exploit the hydrophobic effect and lead to lower off rates, such that higher affinities are achieved.
2. Incorporating charged groups that exploit long-range ionic interactions, leading to faster on rates and to higher affinities (see for example Schreiber *et al*, *Rapid, electrostatically assisted association of proteins* (1996), Nature Struct. Biol. 3, 427-31)
 10
3. Incorporating additional constraint into the peptide, by i.e.
 - Constraining side chains of amino acids correctly such that loss in entropy is minimal upon target binding
 - 15 - Constraining the torsional angles of the backbone such that loss in entropy is minimal upon target binding
 - Introducing additional cyclisations in the molecule for identical reasons.

(for reviews see Gentilucci et al, Curr. Pharmaceutical Design, (2010), 16, 3185-203, and
 20 Nestor et al, Curr. Medicinal Chem (2009), 16, 4399-418).

Tryptophan and hydrophobic analogue substitutions:

Initially, a range of hydrophobic amino acids were substituted into the Trp2 site to identify candidates that could replace the oxidation sensitive tryptophan, and to identify candidates that could increase potencies (addressing the first point above). The side
 25 chains of these amino acids are shown in Figure 12, and affinity data is summarised in Table 12 below.

As expected, none of the modifications increase plasma stability. 2-Naphtylalanine is most closely related to Trp2 and displays a potency slightly weaker than wildtype, making this a good, oxidation-resistant replacement for Trp2. Interestingly, 3,3-DPA2 has a

structure that is very dissimilar to Trp, yet the corresponding peptide retains high potency. This may indicate that the Trp contacting pocket on Kallikrein could be exploited for higher affinity binding by identifying a correctly designed hydrophobic entity.

Proline Analogues:

5 Next, we were interested in determining the role of Pro3 in the WPAR pharmacophore in Ac-06-34-18(TMB)-NH₂. 4-hydroxy- or 4-fluoro-*trans* (L)-proline (HyP3, 4FluoPro3) were chosen for their known property in inducing additional rigidity and helicity on the peptide backbone (Figure 13, Table 13). Additionally, the presence of the hydroxyl on HyP probes the solvent accessibility of the proline side chain. Ki's of the respective derivatives were
10 almost identical to that of wildtype, indicating that any effects on the peptide backbone are negligible, but also demonstrating that the side chain is accessible. To elaborate this further, two additional derivatives of Ac-06-34-18(TMB)-NH₂ were tested, which contained bulky extension on the γ -carbon of the Pro3 sidechain (4Phenyl-Pro, 4Benzyl-Pro). The former displayed a striking preservation of potency, while the latter was
15 severely impacted, demonstrating that the Pro side chain is accessible, but limited to distinct modifications only. Despite the steric bulk in these modifications, plasma stability was identical to that of wildtype. Thus, these modifications do not improve selectivity against other proteases.

To probe the effect of proline ring size on binding, the highly constrained 4-membered
20 Pro analogue azetidine carboxylic acid (Aze), and the more flexible 6-membered ring (pipecolic acid, Pip) were substituted for Pro3. Ac-06-34-18(TMB)-NH₂ Aze3 binds Kallikrein with the highest affinity of all derivatives so far, surpassing that of wildtype by a factor of 3 (Figure 14, Table 13). There appears to be an inverse relationship between ring size and Ki, which would suggest that conformational constraint at position 3 of Ac-
25 06-34-18(TMB)-NH₂ is key to a tightly binding molecule.

The flexibility of the proline side chain in tolerating large bulky groups is underlined by the bi/tricyclic proline analogues Tic, NorHar and Ind (Figure 13). Particularly for the latter two cases, affinities are still well in the one digit nanomolar range.

Finally, we sought to probe the requirement for the ring structure at Pro3 altogether. To
30 this end, we chose aminoisobutyric acid (Aib, Figure 15, Table 13), which, due to its double methyl substitution at the alpha carbon, has a strong structural effect on the neighbouring amino acids in inducing α or 3_{10} helicity (Toniolo *et al* (1993), Biopolymers 33, 1061-72; Karle *et al* (1990), Biochemistry 29, 6747-56). Remarkably, this non-

natural non-cyclic amino acid is well tolerated in place of Pro3, at a K_i of 1.2 nM. Thus, the role of Pro3 in the WPAR pharmacophore is to introduce a constraint onto the peptide backbone. This constraint can be enhanced by employing a proline analogue with reduced ring size (see Aze3). Conversely, the proline ring can be replaced relatively efficiently with non-cyclic but structure-inducing amino acids, such as Aib.

Miscellaneous Analogues:

In table 10, it was shown that Ser1 in loop 1 of Ac-06-34-18(TMB)-NH₂ could be N-methylated with very minor impact on potency (0.5 versus 0.17 nM K_i in WT). We sought to determine whether this location tolerated a large double substitution on C α at position 1. To this end, Ser1 was replaced with Dpg (dipropylglycine) (Figure 15). The affinity of this peptide to Kallikrein is at 1.1 nM, indicating that position 1 is very flexible in accommodating virtually any bulky residue. Thus, this position in loop 1 could be exploited for deliberate inclusion of desirable chemical functionalities or groups, including solubilising amino acids, radio labels, dye labels, linkers, conjugation sites *et cetera*.

Several alanine analogues were also tested at position 4. As already seen with the N-methyl and D-alanines (Table 10, 9), Ala4 is highly sensitive to the steric orientation at C α , or to modification on the backbone itself. Two more derivatives of this class underline this, as elongation of the peptide backbone at Ala4 (β -Ala4) dramatically reduces affinity (~20 μ M). As expected from D-Ala4, Aib4 reduces affinity to almost the same extent (289 nM, Figure 15 and Table 14). Remarkably, extension of the Ala sidechain by one methylene (Aba4) appears to enhance the affinity to Kallikrein.

Finally, the central cysteine (Cys2) was replaced with a bulkier and more constrained analogue, penicillamine (Pen, Figure 15) in the hope of increasing proteolytic stability due to reduced spatial access to the neighbouring Arg5 protease recognition point. Indeed, rat plasma stability was slightly enhanced, however potency dropped significantly, underlining the importance of the full integrity of this structural scaffold-connecting residue.

Combination of plasma stability enhancing and potency enhancing non-natural amino acids into a single Bicycle lead

Non-natural substitutions in Ac-06-34-18(TMB)-NH₂ that retained appreciable potency and maximal rat plasma stability (as determined by method #1) were the Arg5 variants homoarginine (HomoArg5), 4-guanidylphenylalanine (4GuanPhe5) and N-methyl arginine

(NMeArg5). Non-natural substitutions in Ac-06-34-18(TMB)-NH₂ that increased potency compared to the wildtype peptide was the Pro3 analogue azetidine carboxylic acid (Aze3) and the Ala4 analogue 2-aminobutyric acid (Aba4). Thus, Aze3, Aba4 were combined with the protease stability enhancing HomoArg5, 4GuanPhe5 and NMeArg5 to determine whether this would yield peptide candidates with high plasma stability and increased potency.

Table 15 and 16 present the affinities of the various constructs, together with the plasma stabilities.

Firstly, quantitative determination of rat plasma half-lives (4th column, Table 15) of arginine analogue containing peptides revealed that Arg5 N-methylation was most potent in protecting the peptide ($t_{1/2}$ >20 hrs) followed by HomoArg5 and GuanPhe5. The strong protective effect of Arg N-methylation is perhaps not surprising as it directly prevents hydrolysis of the peptide bond. Upon inclusion of Aze3 in these compounds, the affinity of these peptides could be enhanced in all cases, making Ac-(06-34-18) Aze3 HomoArg5 and Ac-(06-34-18) Aze3 NMeArg5 attractive candidates for further development (Table 15, Figure 16).

The affinity enhancing effect of Aba4 could not be reproduced in the context of Aze3 and any of the arginine analogues, as K_i values were higher than those observed without Aba4. Thus, the potency enhancing effects of Aze3 are independent of the type of Arginine substitution, while those of Aba4 are likely not.

Finally, the activity towards rat Kallikrein of these peptides is reduced significantly (Table 15). However, these values are relative and not quantitative at this stage as the protein preparation of rat Kallikrein is not trivial and contained impurities.

Example 6: Plasma stability enhancement of the Trp-free FPYR Kallikrein bicycle lead and affinity enhancement by Aze3

From the selection output in Examples 1-4 we discovered several sequences resembling Ac-06-34-18(TMB)-NH₂ that had a high abundance, but contained altered WPAR motifs. These were WPSR and FPYR. The latter in particular is interesting as it lacks the oxidation-sensitive tryptophan.

Bicycles containing WPSR, FPYR, WPYR and FPAR were synthesised and compared against the WPAR parent peptide (Table 21)

As expected, none of the peptides displayed a significantly different plasma stability. The replacement of Trp2 with Phe2 incurs a 40-fold reduction in K_i , underlining the requirement of the bulkier Trp2 side chain. However, this reduction can be compensated by replacing Ala4 with Tyr4 (giving the FPYR motif), so that the affinity increases again to almost that of the wildtype WPAR sequence ($K_i = 0.46$ nM). Thus, there is a cooperative interplay between the residues at position 2 and position 4 of the Ac-06-34-18(TMB)-NH₂ bicycle. Given the high target binding affinity and lack of Trp2 in Ac-06-34-18(TMB)-NH₂ Phe2Tyr4, this candidate was investigated for increasing rat plasma half life employing the approach as described in the example above. Further, we investigated the interplay between Phe2 and Tyr4 by substituting these residues with non-natural amino acid analogues.

Non-natural substitutions of Phe2/Tyr4 in Ac-06-34-18(TMB)-NH₂ Phe2Tyr4

We performed a non-exhaustive set of syntheses incorporating replacements on Phe2 or Tyr4 in the Ac-06-34-18(TMB)-NH₂ Phe2Tyr4 lead. Non-natural amino acids were chosen from the same set as in Figure 12, and affinity data is summarised in Table 22.

Here, substitution with any of the amino acids tested is generally well tolerated, regardless whether the sidechain is a heteroaromatic (3Pal, 4Pal), aromatic and bulky (1Nal, 2Nal, 4,4-BPal) or a cycloaliphatic (Cha) entity. 3Pal is well tolerated at position 2 ($K_i = 0.91$), which is interesting as Pal contains an ionisable group (which could i.e. be exploited for formulation). It appears, however, that the original Phe2/Tyr4 combination remains most potent.

Stabilisation of Ac-06-34-18(TMB)-NH₂ Phe2Tyr4 in rat plasma and effect of azetidine carboxylic acid 3 substitution

Ac-06-34-18(TMB)-NH₂ Phe2Tyr4 was prepared with the homo-arginine, 4-guanidylphenylalanine and N-methylarginine substitutions, in absence and presence of Aze3. HomoArg/4Guanphe are well tolerated, with K_i values almost identical to the parent Phe2Tyr2 peptide (Table 23), and rat plasma stability was enhanced by a factor of 13 ($t_{1/2} = 12.2$ hrs, Table 23, Figure 16). Moreover, IC₅₀ values for rat Kallikrein are similar to that of parent, indicating this to be an attractive candidate for in vivo studies.

Pro3 to Aze3 substitution in the FPYR context again yielded peptide candidates with enhanced affinity, indeed a peptide with a K_i less than 1 nM was generated that would likely have a greater half-life than 20 hrs in rat (Ac-(06-34-18) Phe2 Aze3Tyr4 NMeArg5).

Example 7: Improving the human plasma stability of the 06-34-18 bicycle lead candidate through single amino acid substitutions in Loop 2

Identification of His7 as a major plasma protease recognition site

5 Rat and human plasma stability of the following loop 1 -modified 06-34-18 peptides were determined quantitatively using LC-MS (Method #3, Table 2). It is clear that the chemical modifications (HArg5, 4GuanPhe5, NMe-Arg5) that impart stability to rat plasma proteases are not effective in the proteolytic context of human plasma.

10 Ac-06-34-18(TMB)-NH₂ Phe2 Tyr4 (referred to as wild type peptide) was subsequently subjected to human plasma, and analysed for fragments to appear over time. This was compared to the degradation profile observed in human plasma using the NMe-Arg5 derivative of 06-34-18 (Figures 18a and 18b). Fragmentation was determined according to Method #2.

15 According to the mass spectrometric information, endo-proteolytic hydrolysis occurs on either the N- and/or C-terminal side of His7 in the 06-34-18 sequence, subsequently excising Leu6 (through an exo-proteolytic activity) or His7-Gln8 (through an exo-proteolytic activity) or all three residues together. From the nature of the fragments observed, it is likely that the initial endoproteolytic hydrolysis event occurs on the peptide bond between Leu6 and His7, rather than between His7 and Gln8. Moreover, the same
20 fragmentation pattern is observed if the rat plasma protease recognition point on Arg5 is blocked with N-methylation (Figure 18b), indicating that the proteolytic specificity of human plasma is distinct from that of rat.

Systematic assessment of the role of Loop 2 residues, and stabilisation against plasma proteases.

25 Subsequently, the role of each of the loop 2 residues in terms of their effects on human plasma stability and human kallikrein potency was assessed.

Using experimental approaches partially outlined in the background to the invention section, a full loop 2 amino acid scan was performed by

30 1) replacing each of the loop 2 amino acids with Alanine to remove the side chain that serves as a recognition point for the protease(s)

2) replacing each of the loop 2 amino acids with their D-amino acid enantiomeric counterparts to sterically oppose access by the degradative protease(s)

3) replacing some of the loop 2 amino acids with D-alanine, to sterically oppose access to the peptide bonds by the protease(s)

5 The potency data for each variant are summarised in Tables 3a, 3b, and 3c, respectively.

1) Alanine Scan of Loop 2 residues

Table 3a shows that modification of His7 with Ala7 appears to reduce proteolytic degradation in the second loop, as -L, -HQ, -LHQ fragments were not detectable. However, proteolytic activity in loop 1 on Arg5 (which was previously observed only with
 10 rat plasma) now becomes detectable. Thus it is clear that human plasma proteases are capable of attacking both proteolytic recognition points (Arg5 and His7). Even though Ala7 appears to enhance stability compared to His7 (as in wildtype peptide), its potency is reduced significantly (56-fold), bringing the K_d to 23 nM, which is not sufficiently potent for a therapeutic molecule. The remaining Ala replacements all reduce potencies to
 15 varying degrees, without increasing plasma stability however (as judged by the appearance of Loop2 degraded Bicycle Peptide fragments, Table 3a fourth column). Together, this underlines the finding that the sidechain of His7 is the protease recognition point.

2) D-Amino Acid Scan of Loop 2 residues

20 Table 3b shows the effect of replacing each of the amino acids with their D- enantiomeric counterparts. This modification leaves the sidechain intact, but projects it in the alternate configuration on C α . The D- amino acids at any position within loop 2 appear to stabilise loop 2 of the peptide from proteolytic degradation; however, as seen with the Ala7 variant above, specificity switches now to the labile site in loop 1 (Arg5). The switch of hydrolysis
 25 to Arg5 made it difficult to quantify the effect of D-amino acid-induced stabilisation in loop2, as this independent process impacts the quantity of remaining parent material (addressed further below). The distal protective effect of D-amino acid substitution has been recognised in the literature and likely functions by sterically reducing or preventing access to the hydrolysable bond (Tugyi et al (2005) PNAS, 102(2), 413–418). However,
 30 D-amino acids progressively further away from the putative His7 protease recognition site (i.e. D-Asp9, D-Leu10) also show a smaller quantity of fragments corresponding to an excised Leucine 6, which is adjacent to His7.

Notably, most of the D-amino acid variants display strongly reduced potencies (between 130 to 9000-fold reduction in potency), underlining the 3-dimensional and steric nature of the interaction of peptide with the kallikrein protein. D-Asp9 appears to be the exception, in that an increase in stability is observed, while 4 nM (9-fold reduction compared to WT) potency is maintained. This modification could potentially be a useful stabilising substitution in a candidate therapeutic molecule.

3) D-Alanine Scan of Loop 2 residues

Table 3c shows the effect of replacing a few select loop 2 amino acids with D-Alanines. Removing the side chains and introducing the steric block on C α due to the presently introduced methyl group has strongly detrimental effects on potencies. Nonetheless, in two cases low nanomolar affinities are retained (Ac-(06-34-18) D-Ala9, and Ac-(06-34-18) Phe2 Tyr4 D-Ala9). As with D-Asp9, these modifications could potentially be a useful stabilising substitution in a candidate therapeutic molecule.

15 Replacement of amino acid sidechains on Leu6, His7 and Gln8 with amino acid mimetics

Subsequently a campaign of amino acid substitution of Leu6, His7 and Gln8 was undertaken to evaluate the steric, charge, and structural requirements of these residues, and to evaluate their effect on reducing recognition of the His7 site by plasma proteases (a structure of Loop2 is presented in Figure 19a).

20 General approaches that are suitable were discussed previously in the introductory section.

- Substitutions at position 6 in Loop2 of 06-34-18

At residue Leu6, it was sought to introduce steric bulk at C β of the amino acid, with the aim of reducing protease access to the scissile bond between Leu6 and His7. The structures tested are shown in Figure 19b. The effect on potency is summarised in Table 24a. Some of the modifications show enhancement of affinities compared to the wildtype peptide, particularly in the context of Ac-(06-34-18) (less so in the context of Ac-(06-34-18) Phe2 Tyr4). Specifically, these are the non-natural amino acids phenylglycine (Phg) and cyclohexylglycine (Chg). All of these modifications appeared to somewhat reduce the proteolytic cleavage in the second loop, but the most potent stabiliser proved to be tert-butylglycine (tBuGly). This peptide, Ac-(06-34-18) Phe2 Tyr4 tBuGly6, showed only

removal of Arg5 in the first loop when subjected to human plasma. Together, any of the Chg, Phg, and tBuGly modifications could serve to enhance second loop plasma stability. In addition, we identified two modifications (Chg, Phg) that enhance the potency towards Kallikrein.

5 • Substitutions at position 7 in Loop2 of 06-34-18

At residue 7, the effect on plasma stability and potency by replacing the histidine side chain was studied employing the following mimics: The pyridylalanines 2Pal, 3Pal, 4Pal are basic ionisable heteroaromatic mimics of the imidazole sidechain. Thienylalanine (Thi), furylalanine (FuAla), ThiAz, 1,2,4 triazolalanine, (1,2,4 Triaz), thiazolylalanine (ThiAz) are 5-membered heteroaromatic uncharged mimics of the imidazole side chain. His1Me/His3Me are N-methyl substituted derivatives of the imidazole side chain. Dap, Agb and Agp represent positive charge replacements of the imidazole side chain, lacking an aromatic sidechain however (Figure 19c). Table 24b summarises the potency data. Strikingly, all peptides display an enhanced stability towards plasma proteases in loop2, visible degradation occurred only in Loop 1 on Arg5. Clearly, a positive charge at position 7 is not sufficient to provide a recognition point for plasma proteases (Dap, Agp, Agb). Conversely, removal of the positive charge while retaining close mimicry of the original imidazole side chain also removes the proteolytic recognition site. Despite the very close mimicry of some of structures to the original imidazole ring, all of the peptide derivatives display a significantly reduced affinity to plasma kallikrein. This indicates that the intact structure of His 7 is required for binding to kallikrein with full potency. Interesting candidates that retained low-nanomolar binding were thiazolylalanine, furylalanine, and His1Me. Interesting putative candidates could be homohistidine, and imidazolyglycine.

 • Substitutions at position 8 in Loop2 of 06-34-18

25 Residue 8 (Gln8) is more distal to the cleavage site that resides between Leu6 and His7. A few substitutions were tested (Figure 19d and Table 24c). Negatively charged amino acids were introduced at this position so as to encourage a salt bridge to the neighbouring His7, which could reduce recognition of His7 by plasma proteases. An additional Loop2 sequence was tested that was present in the phage selection outputs, which also lacked a histidine 7. This loop 2 sequence was LTTEL (referred to as Ac-(06-34-18) Phe2 Tyr4 Thr7 Thr8 Glu9). Additionally, a beta amino acid was tested at position 8 (bHGln8, Figure 19d). A positive charge amino acid was also tested at this position so as to potentially thwart proteolytic recognition of His7 and subsequent degradation. While potencies of these molecules were often < 10 nanomolar, the effect on plasma

stabilisation was minor. These molecules may warrant further quantitative study to determine their precise effects on plasma stability.

Example 8: Improving the human plasma stability of the 06-34-18 bicycle lead candidate through amino acid backbone modifications in Loop 2

Amino acid backbone modification presents a widely recognised means by which the peptide backbone can be protected from protease hydrolysis (for reviews see Gentilucci et al, Curr. Pharmaceutical Design, (2010), 16, 3185-203, and Nestor et al, Curr. Medicinal Chem (2009), 16, 4399-418).

A well-established method in the art is to N-alkylate, for example N-methylate the $N\alpha$ of amino acids. Table 25a shows the effect of systematic replacement of loop two amide backbones with their $N\alpha$ -methylated counterparts. In principle, this is a very effective hydrolysis-protective modification, as not only the peptide bond itself is protected from proteolytic hydrolysis, but also as the bulk of the methyl group on the $N\alpha$ has protective effects on neighbouring peptide bonds. Indeed, strongly protective effects on loop2 proteolysis are observable, however potencies invariably decrease by a factor of 100 or greater. As with D-amino acid replacement, N-alkylation protects the scissile site at His7 even when it is present at Asp9 or Leu10.

Another means by which the peptide backbone can be modified is by N-alkylation of the $N\alpha$ with an appropriate amino acid side chain (termed peptoid). The homohistidine sidechain was introduced at the $N\alpha$ of His7, while concomitantly removing the side chain on $C\alpha$ of His7, yielding an N-alkyl glycine. The structure of this derivative is shown in Figure 20a (termed N-His7), within the context of the entire second loop of 06-34-18.

In an attempt to modify the structure of the peptide backbone itself, a reduced form of the peptide bond was introduced between Leu6 and His7 (Figure 20b). Here, Leu6 was replaced by Ala6, and the carbonyl on this residue was reduced to methylene, yielding a linkage that lacks the native peptide bond altogether. This derivative is referred to as "reduced amide" or "pseudo peptide bond", and termed ψCH_2NH . Due to the absence of the carbonyl on this position, the peptide cannot be hydrolysed at this position and should infer favourable protease stability characteristics to the peptide.

In the plasma assay, both peptide derivatives (Ac-(06-34-18) Phe2 Tyr4 N-His and Ac-(06-34-18) Phe2 Tyr4 Ala(ψ CH₂NH)6) displayed significantly enhanced stability in loop2. Fragments observed solely corresponded to degradation in Loop 1, on Arg5. Potency data is summarised in Table 25b. As expected, the N-His derivative showed strongly reduced binding. However, the pseudo amide peptide Ac-(06-34-18) Phe2 Tyr4 Ala(ψ CH₂NH)6 retained a very good potency at a K_d of 1.5 nM.

Example 9: Generation of potent, rat and human plasma-stable, cross-reactive Bicyclic Peptide leads by selective chemical modification in both Loop 1 and Loop

2

From the preceding two examples, several loop 2 modifications were identified that enhanced protease stability in loop2, while displaying a good potency. Retention of an appropriate potency towards rat plasma kallikrein is desirable for establishing PK/PD in animal models. The comparative rat potency is summarised for suitable loop2 stability-enhanced candidates in Table 26a. Most of the molecules display potencies <100 nM towards rat plasma kallikrein.

In Examples 1-6, methods have been disclosed by which Loop 1 of 06-34-18 can be stabilised against plasma proteases. These advantageous modifications are combined with the plasma stability enhancing modifications in Loop 2 (Examples 7, 8). Several representative candidates were prepared and assessed for human/rat plasma stability, as well as potency towards human/rat plasma kallikrein (Table 26b).

Notably, most of the peptides display, when in combination with the loop 1 modifiers, better potencies towards human and rat kallikrein than peptides with the loop 2 modifiers alone (Table 26a). Most of the potencies are in a range acceptable for therapeutic and PK/PD purposes (see human and rat kallikrein data, Table 26b).

Due to the introduction of HArg5 in place of Arg5 in loop1, and due to the introduction of modifications in loop2 that reduced proteolysis at the His 7 site, the peptides shown in Table 26a and 26b should display enhanced stability in both human and rat plasma.

Plasma stability was assessed comparatively as before using the MALDI TOF assay (Methods #1 and #2), and formation of peptidic hydrolysed fragments was observed over time (for wildtype stability, see figures 18a, 21a, 21b). Compared to wildtype peptide, the multivariant peptides Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 Ala(ψ CH₂NH)6 (human

plasma stability: Figure 21d, rat plasma stability: Figure 21 e) and Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 D-Asp9 (human plasma stability: Figure 21c) display a remarkably enhanced stability in both human rat plasma .

Together, this shows that suitable modifications both in Loop 1 and Loop 2 of 06-34-18 can be combined to yield highly potent, cross-reactive, and plasma stable bicyclic peptides, which display a profile suitable for therapeutic purposes.

Example 10: Advantageous in vivo pharmacokinetic properties of two lead peptides, Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 Ala(ψ CH₂NH)₆ and Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 D-Asp9

Peptides Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 Ala(ψ CH₂NH)₆ (which contains the affinity enhancing modifications Aze3 and the plasma protease stability enhancing modifications HArg5 and the plasma protease stability enhancing reduced amide bond between Ala6 and His 7 in Loop2) and Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 D-Asp9 (which contains the affinity enhancing modification Aze3 and the plasma protease stability enhancing modifications HArg5 and D-Asp9 in Loop2) were selected for pharmacokinetic assessment in rat. The full chemical structure of Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 Ala(ψ CH₂NH)₆ is shown in Figure 22.

The clearance rates from the rat circulation for both peptides were assessed and compared to a control peptide that was composed of the Ac-(06-34-18)(TMB) sequence whose amino acids were replaced by each of the respective D-enantiomers (the sequence thus being "(Ac-cswpardlhqdlc-NH₂(TMB)). This control peptide has identical atomic and sequence composition, retains similar physico-chemical properties, lacks any potency towards the kallikrein target, and importantly is completely resistant to proteolytic activities. Thus, the clearance from the rat circulation of the all D Ac-06-34-18 control peptide is driven mostly renally, as the proteolytically-driven clearance is absent. Any optimised protease-stabilised and potent kallikrein-inhibiting Bicycle that is based on the 06-34-18 sequence should therefore clear from the rat circulation at a rate similar to the control All-D 06-34-18 peptide.

Peptides were applied as intravenous boli in PBS-buffered solution at 1.02 mg/mL (containing 2.9% DMSO) at 5.2 mg/kg to Sprague Dawley rats, and serial blood samples

were taken from each animal via temporary indwelling tail vein cannulae at 5, 10, 20, 30, 60, 120, and 240 minutes post dose, and transferred to EDTA tubes for plasma generation. Data was acquired for peptide “all D Ac-06-34-18” from 3 rats, for “Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 Ala(ψ CH₂NH)₆” from two rats, and for “Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 D-Asp9” from two rats.

Plasma samples were then treated with 3 volumes of a 1:1 mixture of acetonitrile and methanol, precipitated proteins were removed by centrifugation, and the supernatant was analysed by UPLC-MS/MS.

Quantification for peptide content in the samples was by reference to a calibration line prepared in control rat plasma. Pharmacokinetic parameters were determined by non-compartmental analysis using the software package PK Solutions 2.0 from Summit Research Services.

The peptide (Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 Ala(ψ CH₂NH)₆ displayed an elimination half-life of 48 minutes, while the control All D 06-34-18 peptide cleared at a 54 minute half-life. The volumes of distribution for the two peptides were comparable (Table 27, Figure 23). Thus, the pharmacologically active (Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 Ala(ψ CH₂NH)₆ peptide is as stable as the pharmacologically inert protease stable All D 06-34-18 control peptide, indicating that (Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 Ala(ψ CH₂NH)₆ has favorable properties for further development as a therapeutic (Figure 23). Peptide Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 D-Asp9 cleared more rapidly, however, with an elimination half-life of ~27 minutes.

The intravenous pharmacokinetic parameters for the 3 peptides are summarised in Table 27.

The results underline the enhanced proteolytic stability of peptide Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 Ala(ψ CH₂NH)₆ in the in vivo circulation of the rat. The clearance at 5.8 mL/min/kg is very close to the published renal filtration rate in rat (~8-9 mL/min/kg), indicating that plasma protease-driven clearance of this Bicyclic peptide is virtually absent [Jobin J, Bonjour JP, (1985) Am J Physiol.;248(5 Pt 2):F734-8].

Unless otherwise stated, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. Methods, devices, and materials suitable for such uses are described above. All publications cited herein are incorporated herein by reference in their entirety for the purpose of describing and disclosing the methodologies, reagents, and tools reported in the publications that might be used in connection with the invention.

Tables

Table 1:

Potencies, Rat plasma stability and species cross reactivity of Ac-06-34-18 as disclosed in PCT/EP2012/069898. ¹Determined according to Method #1. ²Determined according to Method #3. Table reproduced from PCT/EP2012/069898.

Peptide	Ki (nM) (human kallikrein)	Observable in rat plasma, for days ¹	t _{1/2} (hrs) in rat plasma ²	Ki (nM) (rat kallikrein)
Ac-(06-34-18) wildtype	0.17	2.0	2.3	1.8
Ac-(06-34-18) HomoArg5	2.1	>10	10.7	101
Ac-(06-34-18) 4GuanPhe5	0.34	>10	2.8	3.0
Ac-(06-34-18) NMeArg5	3.5	>10	>20	119.7
Ac-(06-34-18) Aze3 HomoArg5	0.14	>10	nd	14.8
Ac-(06-34-18) Aze3 4GuanPhe5	0.17	>10	nd	nd
Ac-(06-34-18) Aze3 NMeArg5	1.3	>10	nd	70.2
Ac-(06-34-18) Phe2 Tyr4 wildtype	0.46	2	0.9	7.6
Ac-(06-34-18) Phe2 Tyr4 HomoArg5	0.77	>10	12.2	16.2
Ac-(06-34-18) Phe2 Tyr4 4GuanPhe5	0.40	>10	5.0	0.6
Ac-(06-34-18) Phe2 Tyr4 NMeArg5	3.56	>10	>20	64.3
Ac-(06-34-18) Phe2 Aze3 Tyr4 HomoArg5	0.12	nd	nd	3.0
Ac-(06-34-18) Phe2 Aze3Tyr4 4GuanPhe5	0.36	nd	nd	1.2
Ac-(06-34-18) Phe2 Aze3Tyr4 NMeArg5	0.97	nd	nd	31.4

Table 2:

Summary of the ex vivo rat and human plasma stabilities of different Loop1-modified 06-34-18 peptide derivatives, as determined by Method #3.

	Ki(nM) human Kal	Rat Plasma Stability (t1/2 in hrs)	Human Plasma Stability (t1/2 in hrs)
Ac-06-34-18 Phe2 Tyr4	0.42	0.9	1.4
Ac-06-34-18 Phe2 Tyr4 NMeArg5	4	> 20	1.7
Ac-06-34-18 Phe2 Tyr4 HomoArg5	0.77	12.2	2.1
Ac-06-34-18 Phe2 Tyr4 GuanidylPhe5	0.4	5	2.9

Table 3a:

Alanine Scan in Loop2. Resultant potencies are compared to WT, and peptide fragments observed after incubation in human plasma are noted.

Alanine Scan of Ac-(06-34-18) Phe2 Tyr4	Ki (nM)	F (Ki _{var} /Ki _{WT})	Fragments (human plasma)
Ac-(06-34-18) Phe2 Tyr4 (wild type)	0.42	1	-LHQ
Ac-(06-34-18) Phe2 Tyr4 Ala6	1.90	5	-LHQ, -R
Ac-(06-34-18) Phe2 Tyr4 Ala7	23.43	56	-R
Ac-(06-34-18) Phe2 Tyr4 Ala8	1.74	4	-LHQ, -R

Ac-(06-34-18) Phe2 Tyr4 Ala9	1.58	4	-LHQDL, -R
Ac-(06-34-18) Phe2 Tyr4 Ala10	13.46	32	-LHQ, -LHQDL, -R

Table 3b:

D-amino acid Scan in Loop2. Resultant potencies are compared to WT, and peptide fragments observed after incubation in human plasma are noted.

D-amino acid scan	Ki (nM)	F ($K_{i_{var}}/K_{i_{WT}}$)	Fragments (human plasma)
Ac-(06-34-18) Phe2 Tyr4 D-Leu6	9078.33	21615	-R, -FPYR
Ac-(06-34-18) Phe2 Tyr4 D-His7	129.18	308	-R, -FPYR
Ac-(06-34-18) Phe2 Tyr4 D-Gln8	316.90	755	-R, -FPYR
Ac-(06-34-18) Phe2 Tyr4 D-Asp9	3.89	9	-R, -FPYR
Ac-(06-34-18) Phe2 Tyr4 D-Leu10	415.67	990	-R, -FPYR

Table 3c:

D-Alanine Scan in Loop2. Resultant potencies are compared to WT. Fragments were similar to those seen with the full D-amino acid replacements (Table 3b). Note that both Ac-(06-34-18) and Ac-(06-34-18) Phe2 Tyr4 were also assessed.

D-Alanine Scan	Ki (nM)	F ($K_{i_{var}}/K_{i_{WT}}$)
Ac-(06-34-18) D-Ala6	1037.00	2469
Ac-(06-34-18) D-Ala8	11.67	28
Ac-(06-34-18) D-Ala9	0.87	2

06-56	ACGGPQNCRTWTTCA	A	C	G	G	G	P	Q	N	C	R	T	W	T	T	C	A	2.1	>10000	>10000
06-157	ACNWPYRCLHTDLCA	A	C	N	W	P	P	Y	R	C	L	H	T	D	L	C	A	3.3	>10000	>10000
06-61	ACSWPYRCLHQDYCA	A	C	S	W	P	P	Y	R	C	L	H	Q	D	Y	C	A	5.8	>10000	>10000
06-64 T	ACGVPYRCTHQEMCA	A	C	G	V	P	P	Y	R	C	T	H	Q	E	M	C	A	6.9	>10000	>10000
06-A2*	ACTWPARCTMQNWCA	A	C	T	W	P	P	A	R	C	T	M	Q	N	W	C	A	181		>10000
06-63 T	ACADPWACLFRRPCA	A	C	A	D	P	P	W	A	C	L	F	R	R	P	C	A	1277	>10000	>10000
1E6	ACAWPARCLTTSLCG	A	C	A	W	P	P	A	R	C	L	T	T	S	L	C	G	0.16	>10000	>10000
2A10	ACTYPYKCLHQNLC	A	C	T	Y	P	P	Y	K	C	L	H	Q	N	L	C	A	4.98		
1B1	ACAWPAKCLTRELCA	A	C	A	W	P	P	A	K	C	L	T	R	E	L	C	A	8.1		
1F7	ACGGYNNCRAFSYCA	A	C	G	G	Y	Y	N	N	C	R	A	F	S	Y	C	A	2.2		

Table 5: 06-34 – substitutions based on identification of non-critical residues with natural amino acids

Peptide	Sequence	IC50 human PK (nM)	IC50 rat PK (nM)
06-34	ACRWPARCVHQDLCA*	0.19	7.38
06-34-01	AC <u>S</u> WPARCVHQDLCA	0.15	6.12
06-34-02	ACRWPARC <u>T</u> HQDLCA	0.16	1.09
06-34-03 (01+02)	AC <u>S</u> WPARC <u>T</u> HQDLCA	0.082	0.87
06-34-04	ACRWPARC <u>M</u> HQDLCA	0.075	0.56
06-34-05	ACRWPARC <u>L</u> HQDLCA	0.076	0.62
06-34-17 (01+04)	AC <u>S</u> WPARC <u>M</u> HQDLCA	0.073	0.44
06-34-18 (01+05)	AC <u>S</u> WPARC <u>L</u> HQDLCA	0.070	0.56
06-34-19 (01+05+R/K)	AC <u>S</u> WPA <u>K</u> <u>C</u> <u>L</u> HQDLCA	0.19	4.67

*: Residue numbering is from left to right, where residues 1-5 are in loop 1, and residues 6-10 are in loop 2.

Table 6: 06-34 – substitutions based on identification of non critical residues with N-methylated amino acids

Peptide	Sequence	Ki human PK (nM)
06-34	ACRWPARC V HQDLCA	0.128
06-34-03 – Ala1,6	AC A WPARC A HQDLCA	0.147
06-34-03 - N-MeGly1,6	AC(N-MeG)WPARC(N-MeG)HQDLCA	24.8
06-34-18	AC S WPARC L HQDLCA	0.040
06-34-18 –N-MeSer1	AC(N-MeS)WPARC L HQDLCA	0.560

Table 7

Supplier	Short name	Full chemical name
AGTC	D-Asp	Fmoc-D-Asp(tBu)-OH
Anaspec	NDM-Arg	Fmoc-N ω dimethyl-L-arginine
Anaspec	NMe-Ser	Fmoc - N α - methyl - O - t - butyl - L - serine
Anaspec	NMe-Trp	Fmoc - N α - methyl - L - tryptophan
Anaspec	NorHar	Fmoc-L-1;2;3;4-tetrahydro-norharman-3-carboxylic acid
Anaspec	4PhenylPro	Fmoc-(2S,4S)-4-phenyl-pyrrolidine-2-carboxylic acid
Iris Biotech	Agb	Fmoc-L-Agb(Boc)2-OH
Iris Biotech	Agp	Fmoc-L-Agp(Boc)2-OH
Iris Biotech	β -Ala	Fmoc-beta-Ala-OH
Iris Biotech	Cit	Fmoc-Cit-OH
Iris Biotech	D-Cys	Fmoc-D-Cys-OH
Iris Biotech	β -HArg	Fmoc-L-beta-HArg(Pbf)-OH
Iris Biotech	NMe-Arg	Fmoc-L-MeArg(Mtr)-OH
Iris Biotech	3Pal	Fmoc-L-3Pal-OH
Iris Biotech	4Pal	Fmoc-L-4Pal-OH
Iris Biotech	Pen	Fmoc-Pen(Trt)-OH
Iris Biotech	D-Pro	Fmoc-D-Pro-OH
Iris Biotech	Tic	Fmoc-L-Tic-OH
Iris Biotech	D-Trp	Fmoc-D-Trp-OH
Merck Novabiochem	Aib	Fmoc-Aib-OH
Merck Novabiochem	D-Ala	Fmoc-D-Ala-OH
Merck Novabiochem	D-Arg	Fmoc-D-Arg(Pbf)-OH
Merck Novabiochem	4GuanPhe	Fmoc-Phe(bis-Boc-4-guanidino)-OH
Merck Novabiochem	D-Gln	Fmoc-D-Gln(Trt)-OH
Merck Novabiochem	D-His	Fmoc-D-His(Trt)-OH
Merck Novabiochem	Hyp	Fmoc-Hyp(tBu)-OH
Merck Novabiochem	D-Leu	Fmoc-D-Leu-OH
Merck Novabiochem	NMe-Ala	Fmoc-L-MeAla-OH
Merck Novabiochem	NMe-Cys	Fmoc-N-Me-Cys(Trt)-OH
Merck Novabiochem	SDMA	Fmoc-SDMA(Boc)2-ONa
Merck Novabiochem	HArg	Fmoc-L-HArg(Boc)2-OH
Peptech Corporation	4,4-BPAI	Fmoc-L-4, 4'-Biphenylalanine
Peptech Corporation	3,3-DPA	Fmoc-L-3,3-Diphenylalanine
Peptech Corporation	Dpg	Fmoc-Dipropylglycine
Peptech Corporation	1NAI	Fmoc-L-1-Naphthylalanine
Peptech Corporation	2NAI	Fmoc-L-2-Naphthylalanine
Peptech Corporation	Pip	Fmoc-L-Pipecolic acid
Polypeptide Group	Aba	Fmoc-L-2-aminobutyric acid
Polypeptide Group	Aze	Fmoc-L-azetidine-2-carboxylic acid
Polypeptide Group	4BenzylPro	(2S,4R)-Fmoc-4-benzyl-pyrrolidine-2-carboxylic acid
Polypeptide Group	Cha	Fmoc-beta-cyclohexyl-L-alanine
Polypeptide Group	4FluoPro	(2S,4R)-Fmoc-4-fluoro-pyrrolidine-2-carboxylic acid

Polypeptide Group	Ind	Fmoc-L-Indoline-2-carboxylic acid
AGTC	D-Asp	Fmoc-D-Asp(tBu)-OH
Merck Chemicals	Thi	Fmoc-L-Thi-OH
Sigma	4ThiAz	Fmoc- β -(4-thiazolyl)-Ala-OH
Santa Cruz Biotechnology	1,2,4-TriAz	Fmoc-3-(1,2,4-triazol-1-yl)-Ala-OH
Combi-Blocks	4FuAla7	Fmoc-L-2-Furylalanine
Fluorochem	N-His	2-(1-Trityl-1H-imidazol-4-yl)-ethylamine
Iris Biotech	Agb	Fmoc-L-Agb(Boc)2-OH
Iris Biotech	Agp	Fmoc-L-Agp(Boc)2-OH
Merck	1MeHis	Fmoc-1-methyl-L-histidine
Merck	3MeHis	Fmoc-3-methyl-L-histidine
Sigma	bHGln	Fmoc- β -Homogln(Trt)-OH
Iris Biotech	3Pal	Fmoc-L-3Pal-OH
Iris Biotech	4Pal	Fmoc-L-4Pal-OH
Merck Novabiochem	D-Leu	Fmoc-D-Leu-OH
Merck Novabiochem	HArg	Fmoc-L-HArg(Boc)2-OH
Polypeptide Group	Aze	Fmoc-L-azetidine-2-carboxylic acid
Combi Blocks	Ala-H	Fmoc-L-Alanine aldehyde
Combi Blocks	FuAla	Fmoc-L-2-furylalanine

Table 8

Peptide	Sequence	Ki (nM) (human kallikrein)	Observable in rat plasma, for days
Ac-(06-34-18) wildtype	Ac-CSWPARCLHQDLC	0.17	2
Ac-(06-34-18) A2A3	Ac-CSAAARCLHQDLC	18545	1
Ac-(06-34-18) A2Q3	Ac-CSAQARCLHQDLC	15840	1
Ac-(06-34-18) Scram1	Ac-CPSAWRCLHQDLC	1091	2
Ac-(06-34-18) Scram2	Ac-CWASPRCLHQDLC	11355	2
Ac-(06-34-18) Scram3	Ac-CAPWSRCLHQDLC	1892	1
Ac-(06-34-18) Scram4	Ac-CWARSPLHQDLC	67500	1

Table 9

Comparative effects of D-amino acid substitution on potency and rat plasma stability.

Peptide	Ki (nM) (human kallikrein)	Observable in rat plasma, for days
Ac-(06-34-18) wildtype	0.17	2
Ac-(06-34-18) D-Trp2	7558	2
Ac-(06-34-18) D-Pro3	680	3
Ac-(06-34-18) D-Ala4	1203	>10
Ac-(06-34-18) D-Arg5	52	>10
Ac-(06-34-18) D-Cys2	234	>10

Table 10

Comparative effects of N-methylation of loop 1 residues and Cys2 on potency and rat plasma stability.

Peptide	Ki (nM) (human kallikrein)	Observable in rat plasma, for days
Ac-(06-34-18) wildtype	0.17	2
Ac-(06-34-18) NMeSer1	0.5	3
Ac-(06-34-18) NMeSer1, NMeAla4	444	>10
Ac-(06-34-18) NMeTrp2	228	5
Ac-(06-34-18) NMeAla4	343	>10
Ac-(06-34-18) NMeArg5	3.5	>10
Ac-(06-34-18) NMeCys2	418	10

Table 11

Comparative effects of arginine analogues in Ac-06-34-18(TMB)-NH₂ on potency and stability. Note that the Δ Arg modification did not display any inhibition up to 100 μ M peptide.

Peptide	Ki (nM) (human kallikrein)	Observable in rat plasma, for days
Ac-(06-34-18) wildtype	0.17	2
Ac-(06-34-18) HomoArg5	2.1	>10
Ac-(06-34-18) Agb5	83	>10
Ac-(06-34-18) Agp5	1770	>10
Ac-(06-34-18) β homoArg5	8.2	>10
Ac-(06-34-18) 4GuanPhe5	0.3	>10
Ac-(06-34-18) SDMA5	1415	>10
Ac-(06-34-18) NDMA5	510	>10
Ac-(06-34-18) Cit5	7860	>10
Ac-(06-34-18) Δ Arg5	>100000	>10

Table 12

Comparative affinity effects of hydrophobic amino acids substituting Trp2 in Ac-06-34-18(TMB)-NH₂

Peptide	Ki (nM) (human kallikrein)	Observable in rat plasma, for days
Ac-(06-34-18) wildtype	0.17	2
Ac-(06-34-18) 1NAL2	10.7	2
Ac-(06-34-18) 2NAL2	0.50	2
Ac-(06-34-18) 3Pal2	59	2
Ac-(06-34-18) 4Pal2	72	2
Ac-(06-34-18) Cha2	4.7	2
Ac-(06-34-18) 4,4,BPal2	464	2
Ac-(06-34-18) 3,3-DPA2	1.5	2
Ac-(06-34-18) NorHar2	24	2

Table 13

Comparative affinities obtained for proline derivatives with gamma-carbon substituents, analogues of varying ring sizes, bi/tricyclic derivatives, and constrained amino acids such as Aib

Peptide	Ki (nM) (human kallikrein)	Observable in rat plasma, for days
Ac-(06-34-18) wildtype	0.17	2
Ac-(06-34-18) HyP3	0.41	2
Ac-(06-34-18) 4FluoPro3	0.24	2
Ac-(06-34-18) 4Phenyl Pro3	0.58	2
Ac-(06-34-18) 4Benzyl Pro3	191	2
Ac-(06-34-18) Aze3	0.06	2
Ac-(06-34-18) Pip3	0.26	2
Ac-(06-34-18) Tic3	13.51	2
Ac-(06-34-18) NorHar3	2.99	2
Ac-(06-34-18) Ind3	1.35	2
Ac-(06-34-18) Aib3	1.20	2

Table 14
Comparative effects of miscellaneous substitutions of Ser1, Ala4, and Cys2

Peptide	Ki (nM) (human kallikrein)	Observable in rat plasma, for days
Ac-(06-34-18) wildtype	0.17	2
Ac-(06-34-18) Dpg1	1.09	2
Ac-(06-34-18) Aba4	0.07	2
Ac-(06-34-18) β -Ala4	17450	10
Ac-(06-34-18) Aib4	289	7
Ac-(06-34-18) Cys2ToPen2	2162	5

Table 15

Comparative enhancement in potency induced by incorporation of Aze3 in plasma-stabilised candidates. ¹ Comparative stabilities estimated according to method #1. ² The true half-life of peptide stabilities in rat plasma was determined according to method #3. ³ IC50 values are relative, not absolute.

Peptide	Ki (nM) (human kallikrein)	Observable in rat plasma, for days ¹	t _{1/2} (hrs) in rat plasma ²	IC50 (nM) (rat kallikrein) ³
Ac-(06-34-18) wildtype	0.17	2.0	2.3	1.7
Ac-(06-34-18) HomoArg5	2.1	>10	10.7	64
Ac-(06-34-18) 4GuanPhe5	0.34	>10	2.8	21
Ac-(06-34-18) NMeArg5	3.5	>10	>20	98
Ac-(06-34-18) Aze3 HomoArg5	0.14	>10	nd	nd
Ac-(06-34-18) Aze3 4GuanPhe5	0.17	>10	nd	nd
Ac-(06-34-18) Aze3 NMeArg5	1.30	>10	nd	nd

Table 16

Effect on potency upon inclusion of Aba4 in peptides containing Aze3 and the plasma-stabilising modifications NMeArg5, HomoArg5, and 4GuanPhe5.

Peptide	Ki (nM) (human kallikrein)
Ac-(06-34-18) wildtype	0.17
Ac-(06-34-18) Aze3 Aba4 NMeArg5	2.8
Ac-(06-34-18) Aze3 Aba4 HomoArg5	0.9
Ac-(06-34-18) Aze3 Aba4 4GuanPhe5	0.2

Table 17


42 unique Kallikrein binders were identified from selections using a randomised WPAR motif at positions 2, 3, 4 & 5 within the 06-34-03 sequence. The sequences were ranked according to Kallikrein binding and the relative abundance in the total selection outputs was noted.

Sequence												Rank	Frequency	
C	S	W	P	A	R	C	T	H	Q	D	L	C	1	24
C	S	W	P	S	R	C	T	H	Q	D	L	C	2	51
C	S	F	P	F	R	C	T	H	Q	D	L	C	3	17
C	S	W	L	A	R	C	T	H	Q	D	L	C	4	8
C	S	F	P	Y	R	C	T	H	Q	D	L	C	5	12
C	S	F	P	F	K	C	T	H	Q	D	L	C	6	4
C	S	W	A	A	R	C	T	H	Q	D	L	C	7	1
C	S	H	P	Y	R	C	T	H	Q	D	L	C	8	2
C	S	H	P	F	R	C	T	H	Q	D	L	C	9	1
C	S	W	P	Y	R	C	T	H	Q	D	L	C	10	3
C	R	F	P	F	K	C	T	H	Q	D	L	C	11	1
C	S	F	P	F	R	C	T	H	Q	D	L	C	12	2
C	S	L	P	F	R	C	T	H	Q	D	L	C	13	3
C	S	W	P	F	R	C	T	H	Q	D	L	C	14	7
C	S	F	P	I	R	C	T	H	Q	D	L	C	15	1
C	S	L	P	F	K	C	T	H	Q	D	L	C	16	1
C	S	L	P	F	R	C	T	H	Q	D	L	C	17	4
C	S	Y	P	I	R	C	T	H	Q	D	L	C	18	2
C	S	W	S	A	R	C	T	H	Q	D	L	C	19	10
C	S	L	P	F	K	C	T	H	Q	D	L	C	20	1
C	S	Y	P	F	R	C	T	H	Q	D	L	C	21	1
C	S	F	P	Y	K	C	T	H	Q	D	L	C	22	1
C	S	F	P	W	R	C	T	H	Q	D	L	C	23	1
C	S	W	H	A	R	C	T	H	Q	D	L	C	24	1
C	S	L	P	F	R	C	T	H	Q	D	L	C	25	2
C	S	Y	P	Y	R	C	T	H	Q	D	L	C	26	2
C	S	W	W	A	R	C	T	H	Q	D	L	C	27	1
C	S	W	P	Y	K	C	T	H	Q	D	L	C	28	1
C	S	F	L	Y	K	C	T	H	Q	D	L	C	29	2
C	S	L	P	I	R	C	T	H	Q	D	L	C	30	1
C	S	M	P	Y	R	C	T	H	Q	D	L	C	31	2
C	S	I	P	F	K	C	T	H	Q	D	L	C	32	1
C	S	Y	P	W	R	C	T	H	Q	D	L	C	33	1
C	S	F	P	F	W	C	T	H	Q	D	L	C	34	1
C	S	F	S	Y	K	C	T	H	Q	D	L	C	35	1
C	S	W	S	Y	R	C	T	H	Q	D	L	C	36	1
C	S	F	M	Y	K	C	T	H	Q	D	L	C	37	1
C	S	Q	V	V	G	C	T	H	Q	D	L	C	38	1
C	R	W	P	Y	H	C	T	H	Q	D	L	C	39	1
C	S	L	F	D	H	C	T	H	Q	D	L	C	40	1
C	S	H	R	R	W	C	T	H	Q	D	L	C	41	1
C	S	W	Q	A	R	C	T	H	Q	D	L	C	42	1

Table 18

A. Abundance of particular motif in each output. Output sequences were analysed according to the stringency of selection. The % of a particular motif in the output from a particular stringency selection was calculated. B. Human plasma Kallikrein binding of particular motifs at positions 2, 3, 4 & 5 (with positions 1, 6, 7, 8, 9 & 10 fixed to those of 06-34-03).

A

		Relative abundance of species from different selection stringencies						
Stringency		WPSR	WPAR	WSAR	WPFR	WPYR	FPYR	FPFR
		34	17	3	7	3	7	7
		31	19	3	3	3	3	19
		41	13	3	0	0	3	9
		26	22	7	0	4	7	4
		23	6	6	6	0	16	13
	Low	11	4	11	4	0	4	11




Table 19

Top 50 Kallikrein binders containing a fixed WPAR motif. The WPAR sequence was fixed in a bicycle library with positions 1, 6, 7, 8, 9 & 10 randomised. Kallikrein selection output sequences were isolated and assayed for Kallikrein binding. The sequences were ranked according to Kallikrein binding. The sequence of peptide 06-34-03 was isolated from selection and is highlighted in red. Trends are visible in the second loop of WPAR-containing Kallikrein-binding peptides.

Rank	Sequence													Binding assay signal
1	C	N	W	P	A	R	C	T	H	Q	D	L	C	116
2	C	S	W	P	A	R	C	T	H	Q	D	L	C	110
3	C	H	W	P	A	R	C	T	H	Q	D	L	C	110
4	C	P	W	P	A	R	C	T	H	Q	D	L	C	107
5	C	S	W	P	A	R	C	T	H	A	D	L	C	100
6	C	S	W	P	A	R	C	T	H	D	D	L	C	93
7	C	A	W	P	A	R	C	T	H	T	D	L	C	92
8	C	Q	W	P	A	R	C	L	H	T	D	L	C	91
9	C	L	W	P	A	R	C	T	H	Q	D	L	C	90
10	C	T	W	P	A	R	C	T	H	T	D	L	C	88
11	C	H	W	P	A	R	C	T	H	Q	E	L	C	85
12	C	A	W	P	A	R	C	L	H	D	D	L	C	84
13	C	S	W	P	A	R	C	L	H	T	D	L	C	83
14	C	A	W	P	A	R	C	T	H	V	D	L	C	82
15	C	A	W	P	A	R	C	T	H	T	D	F	C	80
16	C	M	W	P	A	R	C	M	H	Q	D	L	C	79
17	C	A	W	P	A	R	C	T	H	A	D	L	C	79
18	C	Q	W	P	A	R	C	M	H	Q	D	M	C	75
19	C	Q	W	P	A	R	C	T	H	S	D	L	C	74
20	C	L	W	P	A	R	C	T	H	A	D	L	C	74
21	C	R	W	P	A	R	C	T	H	Q	D	L	C	73
22	C	Q	W	P	A	R	C	M	H	Q	E	L	C	73
23	C	T	W	P	A	R	C	L	H	Q	D	L	C	73
24	C	S	W	P	A	R	C	T	H	S	H	L	C	72
25	C	V	W	P	A	R	C	T	H	Q	D	L	C	71
26	C	T	W	P	A	R	C	T	H	A	D	L	C	71
27	C	H	W	P	A	R	C	M	H	Q	D	L	C	71
28	C	P	W	P	A	R	C	T	H	T	D	L	C	70
29	C	A	W	P	A	R	C	T	H	Y	D	L	C	70
30	C	P	W	P	A	R	C	T	H	Q	N	L	C	69
31	C	S	W	P	A	R	C	T	H	T	E	L	C	69
32	C	A	W	P	A	R	C	M	H	D	D	L	C	69
33	C	S	W	P	A	R	C	L	H	T	E	L	C	68
34	C	S	W	P	A	R	C	I	H	Q	D	L	C	68
35	C	T	W	P	A	R	C	T	H	T	D	M	C	67
36	C	A	W	P	A	R	C	T	H	T	H	L	C	66
37	C	A	W	P	A	R	C	L	H	A	D	M	C	66
38	C	A	W	P	A	R	C	L	H	Q	D	W	C	63
39	C	D	W	P	A	R	C	M	H	Q	E	F	C	63
40	C	A	W	P	A	R	C	T	H	Q	T	M	C	61
41	C	T	W	P	A	R	C	L	H	Q	H	M	C	61
42	C	S	W	P	A	R	C	V	H	Q	D	M	C	61
43	C	E	W	P	A	R	C	L	H	T	D	L	C	60
44	C	L	W	P	A	R	C	L	T	T	E	L	C	59
45	C	S	W	P	A	R	C	T	H	A	E	M	C	59
46	C	R	W	P	A	R	C	T	H	T	D	L	C	59
47	C	T	W	P	A	R	C	T	H	Q	A	F	C	59
48	C	S	W	P	A	R	C	T	H	S	D	L	C	59
49	C	S	W	P	A	R	C	L	H	D	D	L	C	59
50	C	P	W	P	A	R	C	L	H	T	D	L	C	58

Table 20

The output sequences from Kallikrein selections with fixed WPAR in the 1st loop, and their associated Kallikrein binding assay signals, were grouped according to their derivation from 'THxxL' motif (A), or 'xHxDL' motif (B). The average binding assay signal for all members of a given group was calculated. Groups containing precisely the given motif are highlighted green; examples of groups with either one more or one less change away from the motif are also shown.

A

Groups based on xHxDL motif					
Motif	Binding	Motif	Binding	Motif	Binding
THxDL	78.5	xHxDL	70.9	xHxxL	56.1
MHxDL	66.7	xHxDM	52.8	xHxxM	46.3
LHxDL	58.0	xHxEL	51.7	xHxxF	43.8
THxEL	55.9	xHxHM	46.4	xHxxW	33.2
THxHL	52.5	xHxNL	46.2	xTxL	31.1
LHxEL	52.3	xHxDW	44.2	xHxxE	19.3
THxNL	51.9	xHxHL	44.2		
THxDW	44.9	xHxFL	40.4		
LHxDW	44.7	xTxEL	39.9		
MHxEL	42.4	xTxDL	39.4		
LTxEL	39.9	xHxQL	39.0		
LTxDL	39.4	xHxAL	35.5		
LHxQL	39.0	xHxSL	35.0		
LHxDM	38.0	xTxSL	33.1		
LHxSL	37.4	xHxYL	29.2		
THxAL	35.5				
LHxHL	34.0				
LTxSL	33.1				
THxSL	28.9				

B

Groups based on THxxL motif					
Motif	Binding	Motif	Binding	Motif	Binding
THxDL	78.5	THxxL	61.0	MHxxx	56.5
MHxDL	66.7	MHxxL	55.0	THxxx	53.4
LHxDL	58.0	LHxxL	47.9	LHxxx	44.4
THxEL	55.9	THxxM	46.3	LTxxx	33.8
THxHL	52.5	LHxxM	39.0		
LHxEL	52.3	LTxxL	38.4		
THxNL	51.9				
THxFL	40.4				
LTxEL	39.9				
LTxDL	39.4				
LHxSL	37.4				
THxAL	35.5				
LHxHL	34.0				
LTxSL	33.1				
THxSL	28.9				

Table 21

Affinities and stabilities of WPAR motif variants.

Peptide	K _i (nM) (human kallikrein)	Observable in rat plasma, for days
Ac-(06-34-18) WPAR	0.17	2
Ac-(06-34-18) FPAR	6.28	2
Ac-(06-34-18) WPYR	0.41	2
Ac-(06-34-18) WPSR	0.44	2
Ac-(06-34-18) FPYR	0.46	2

Table 22

Effect of substitutions on Phe2/Tyr4 with hydrophobic analogues

Peptide	Ki (nM) (human kallikrein)
Ac-(06-34-18) Phe2 Tyr4	0.46
Ac-(06-34-18) Phe2 Cha4	0.91
Ac-(06-34-18) Phe2 3Pal4	2.57
Ac-(06-34-18) Phe2 4Pal4	2.20
Ac-(06-34-18) Phe2 1Nal4	13.5
Ac-(06-34-18) Phe2 2Nal4	7.27
Ac-(06-34-18) Phe2 4,4-BPal4	10.5
Ac-(06-34-18) 3Pal2 Tyr4	0.91
Ac-(06-34-18) 4Pal2 Tyr4	3.56
Ac-(06-34-18) Cha2 Tyr4	1.87

Table 23

Summary of the effect of Arg5 substitutions and Aze3 on Ac-06-34-18(TMB)-NH2 Phe2Tyr4. ¹ Comparative stabilities estimated according to method #1. ² The true half-life of peptide stabilities in rat plasma was determined according to method #3. ³ IC50 values are relative, not absolute.

Peptide	Ki (nM) (human kallikrein)	Observable in rat plasma, for days ¹	t _{1/2} (hrs) in rat plasma ²	IC50 (nM) (rat kallikrein) ³
Ac-(06-34-18) Phe2 Tyr4	0.46	2	0.9	13.8
Ac-(06-34-18) Phe2 Tyr4 HomoArg5	0.77	>10	12.2	19.7
Ac-(06-34-18) Phe2 Tyr4 4GuanPhe5	0.40	>10	5.0	2.5
Ac-(06-34-18) Phe2 Tyr4 NMeArg5	3.56	>10	>20	60.2
Ac-(06-34-18) Phe2 Aze3 Tyr4 HomoArg5	0.12	nd	nd	nd
Ac-(06-34-18) Phe2 Aze3Tyr4 4GuanPhe5	0.36	nd	nd	nd
Ac-(06-34-18) Phe2 Aze3Tyr4 NMeArg5	0.97	nd	nd	nd

Table 24a:

Effect of single amino acid substitutions at position 6. The modifications were tested both in the context of Ac-(06-34-18) Phe2 Tyr4 (left column) and Ac-(06-34-18) (right column).

Residue 6 Modifications	Ki (nM) Ac-(06-34-18) Phe2 Tyr4	Ki (nM) Ac-(06-34-18)
Phe6	14.90	nd
Ile6	1.46	nd
Phg6	0.30	0.18
tBuGly6	3.76	0.49
Chg6	0.50	0.13

Table 24b:

Effect of single amino acid substitutions at position 7. The modifications were tested only in the context of Ac-(06-34-18) Phe2 Tyr4.

Residue 7 Modifications	Ki (nM)	F ($K_{i_{var}}/K_{i_{WT}}$)
Ac-(06-34-18) Phe2 Tyr4 (wild type)	0.42	1
Ac-(06-34-18) Phe2 Tyr4 Phe7	43	102
Ac-(06-34-18) Phe2 Tyr4 Thi7	34	80
Ac-(06-34-18) Phe2 Tyr4 4ThiAz7	14	33
Ac-(06-34-18) Phe2 Tyr4 1,2,4-TriAz7	455	1084
Ac-(06-34-18) Phe2 Tyr4 4FuAla7	17	39
Ac-(06-34-18) Phe2 Tyr4 2Pal7	53	126
Ac-(06-34-18) Phe2 Tyr4 3Pal7	130	308
Ac-(06-34-18) Phe2 Tyr4 4Pal7	79	187
Ac-(06-34-18) Phe2 Tyr4 Dap7	246	586
Ac-(06-34-18) Phe2 Tyr4 Agp7	672	1599
Ac-(06-34-18) Phe2 Tyr4 Agb7	2253	5365
Ac-(06-34-18) Phe2 Tyr4 His1Me7	10	23
Ac-(06-34-18) Phe2 Tyr4 His3Me7	292	696

Table 24c:

Effect of single amino acid substitutions at position 8. The modifications were tested only in the context of Ac-(06-34-18) Phe2 Tyr4.

Residue 8 Modifications	Ki (nM)	F ($K_{i_{var}}/K_{i_{WT}}$)
Ac-(06-34-18) Phe2 Tyr4 Thr8	4.23	10
Ac-(06-34-18) Phe2 Tyr4 Thr7 Thr8 Glu9	81.02	193
Ac-(06-34-18) Phe2 Tyr4 Asp8	3.83	9
Ac-(06-34-18) Phe2 Tyr4 Glu8	2.53	6
Ac-(06-34-18) Phe2 Tyr4 Dap8	5.49	13
Ac-(06-34-18) Phe2 Tyr4 bHGln8	16.83	40

Table 25a:

α -N-methyl amino acid scan in Loop2. Resultant potencies are compared to WT, and peptide fragments observed after incubation in human plasma are noted.

N-methyl scan	Ki (nM)	F (Ki _{var} /Ki _{WT})	Fragments (human plasma)
Ac-(06-34-18) Phe2 Tyr4 NMe-Leu6	57.41	137	-R, -FPYR
Ac-(06-34-18) Phe2 Tyr4 NMe-His7	63.53	151	-R, -FPYR
Ac-(06-34-18) Phe2 Tyr4 NMe-Gln8	62.77	149	-R, -FPYR
Ac-(06-34-18) Phe2 Tyr4 NMe-Asp9	44.29	105	-R, -FPYR
Ac-(06-34-18) Phe2 Tyr4 NMe-Leu10	586.38	1396	-R, -FPYR

Table 25b:

Peptide backbone modifications in Loop2.

Peptide Backbone Modifications	Ki (nM)	F (Ki _{var} /Ki _{WT})
Ac-(06-34-18) Phe2 Tyr4 N-His7	218	519
Ac-(06-34-18) Phe2 Tyr4 Ala(ψ CH ₂ NH)6	1.47	4

Table 26a:

Comparative potencies of loop2 plasma protease stability enhanced candidates towards human and rat plasma kallikrein.

Suitable candidates	Ki (nM) (human kallikrein)	Ki (nM) (rat kallikrein)
Ac-(06-34-18) Phe2 Tyr4 (wild type)	0.90	nd
Ac-(06-34-18) Phe2 Tyr4 D-Asp9	3.89	32.02
Ac-(06-34-18) D-Ala9	0.87	nd
Ac-(06-34-18) Phe2 Tyr4 Phg6	0.30	7.23
Ac-(06-34-18) Phe2 Tyr4 tBuGly6	3.76	218.50
Ac-(06-34-18) Phe2 Tyr4 Chg6	0.50	9.09
Ac-(06-34-18) Phe2 Tyr4 Glu8	2.53	nd
Ac-(06-34-18) Phe2 Tyr4 Ala(ψ CH ₂ NH)6	1.47	43.56

Table 26b:

Comparative potencies of loop 1 and loop 2 -modified 06-34-18 derivatives. Note the inclusion of Aze3 (affinity enhancing) and HArg5 (plasma stability enhancing) modifications in loop 1, and the stability enhancing modifications in loop 2.

Loop1 and Loop 2 multivariants	Ki (nM) (human kallikrein)	Ki (nM) (rat kallikrein)
Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 D-Asp9	0.90	14
Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 Glu8	1.65	23
Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 Ala(ψ CH ₂ NH)6	0.44	41
Ac-(06-34-18) Phe2 Aze3 Tyr4 tBuGly6	1.91	193
Ac-(06-34-18) Aze3 HArg5 Phg6	0.52	57
Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 Phg6	0.32	12

Table 27:

Pharmacokinetic parameters of (Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 Ala(ψ CH₂NH)₆, Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 D-Asp9, and Ac-(06-34-18) All D control in rat. Due to divergent peptide concentrations of Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 D-Asp9 in two individual rats, clearance rates and volumes of distribution could not be calculated with confidence.

Bicyclic Peptide	Clearance based on AUC_{0-∞} (ml/min/kg)	Volume of distribution based on AUC_{0-∞} (L/kg)	t_{1/2} elimination (min)
(Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 Ala(ψ CH ₂ NH) ₆	6.2	0.44	48
Ac-(06-34-18) Phe2 Aze3 Tyr4 HArg5 D-Asp9)	nd	nd	27
Ac-(06-34-18) All D, control	4.5	0.3	54

FURTHER ASPECTS

Further aspects and embodiments of the invention are now set out in the following numbered Paragraphs; it is to be understood that the invention encompasses these aspects:

Paragraph 1. A peptide ligand specific for human Kallikrein comprising a polypeptide comprising at least three reactive groups, separated by at least two loop sequences, and a molecular scaffold which forms covalent bonds with the reactive groups of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold, wherein the loops of the peptide ligand comprises five amino acids and one loop comprises the motif $G_r^T/LH^Q/TxLG_r$.

Paragraph 2. A peptide ligand according to Paragraph 1, wherein the loops of the peptide ligand comprise five amino acids and one loop comprises the motif $G_r x H x D L G_r$, wherein G_r is a reactive group.

Paragraph 3. A peptide ligand according to Paragraph 1, wherein the loops of the peptide ligand comprise five amino acids and one loop comprises the motif $G_r T H x x L G_r$, wherein G_r is a reactive group.

Paragraph 4. A peptide ligand according to any one of Paragraphs 1 to 3, wherein two adjacent loops comprise the motif $G_r x^W/_F P x^K/_R G_r^T/LH^Q/_T D L G_r$.

Paragraph 5. A peptide ligand according to any one of Paragraphs 7 to 11, which comprises one of the polypeptides set forth in Table 4, Table 5, Table 6, Table 25b, Table 26a, Table 26b or Figure 22.

Paragraph 6. A peptide ligand according to any preceding Paragraph, wherein removal of His 7 in loop 2, or replacement of the histidine side chain with any non-charged or charged chemical entities, enhances the stability of the peptide ligand.

Paragraph 7. A peptide ligand according to Paragraph 6, wherein proteolytic stability is enhanced by chemical modification of the peptide bonds N- or C-terminally adjacent to His7.

Paragraph 8. A peptide ligand according to Paragraph 7, wherein the chemical modification is α -N-alkylation, or modification of the peptide bond with its reduced amide form.

Paragraph 9. A peptide ligand according to Paragraph 6, wherein proteolytic stability
5 is enhanced by steric obstruction of nearby amino acids to His 7.

Paragraph 10. A peptide ligand according to Paragraph 9, wherein the steric obstruction results from replacement of position 9 with its D- amino acid enantiomer, or α -N-alkylation.

Paragraph 11. A peptide ligand according to Paragraph 6, wherein proteolytic stability
10 is enhanced by Introduction of sterically obstructive amino acids at position 6.

Paragraph 12. A peptide ligand according to Paragraph 6, wherein proteolytic stability is enhanced by introduction of C β -derivatised amino acids such as phenylglycine or cyclohexylglycine at position 6, which enhance the potency of the peptide ligand sequence towards human plasma kallikrein and reduce the proteolytic hydrolysis of the C-terminal
15 peptide bond.

Paragraph 13. A peptide ligand according to any preceding Paragraph, which comprises one or more non-natural amino acid substituents and is resistant to protease degradation.

Paragraph 15. A peptide ligand according to any preceding Paragraph, wherein the
20 polypeptide comprises a first loop which comprises the motif G_rxWPARG_r or G_rxFPYRG_r and a second loop comprising the motif G_r^{T/L}H^Q/_TxLG_r.


Paragraph 16. A peptide ligand according to Paragraph 15, wherein in the first loop Pro is replaced with azetidine carboxylic acid; and/or the first loop R is replaced with N-methyl arginine; and/or R is replaced with homoarginine; and/or R is replaced with
25 guanidylphenylalanine.

Paragraph 17. A peptide ligand according to Paragraph 16, wherein the polypeptide comprises a first loop which comprises the motif G_rxFPYRG_r, wherein R is replaced with N-

methyl arginine; and/or R is replaced with homoarginine, and/or R is replaced with guanidylphenylalanine, and wherein Pro is replaced with azetidine carboxylic acid.

CLAIMS

1. A peptide ligand specific for human Kallikrein comprising a polypeptide comprising at least three reactive groups, separated by at least two loop sequences, and a molecular scaffold which forms covalent bonds with the reactive groups of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold, in which the loops of the peptide ligand comprises five amino acids and one loop comprises the motif $G_rA(\Psi CH_2NH)H^Q/TX LG_r$, in which G_r is a reactive group and in which X represents any amino acid.
2. A peptide ligand according to Claim 1, in which the polypeptide comprises a first loop which comprises the motif $G_rXWPARG_r$ or $G_rXFPYRG_r$ and a second loop comprising the motif $G_rA(\Psi CH_2NH)H^Q/TX LG_r$.
3. A peptide ligand according to Claim 2, in which in the first loop P is replaced with azetidine carboxylic acid; and/or in the first loop R is replaced with N-methyl arginine or homoarginine or guanidylphenylalanine.
4. A peptide ligand according to Claim 3, in which the polypeptide comprises a first loop which comprises the motif $G_rXFPYRG_r$, in which P is replaced with azetidine carboxylic acid and/or R is replaced with N-methyl arginine or homoarginine or guanidylphenylalanine.
5. A composition comprising a peptide ligand according to any preceding claim together with a pharmacologically appropriate carrier.
6. A peptide ligand according to any of Claims 1 to 4 for use in suppressing or treating inflammatory states, allergic hypersensitivity, cancer, bacterial or viral infection, ophthalmic disorders and autoimmune disorders.
7. A peptide ligand for use according to Claim 6, in which the peptide ligand comprises: Cys Ser1 Phe2 Aze3 Tyr4 HArg5 Cys Ala(ψCH_2NH)6 His7 Gln8 Asp9 Leu10 Cys.
8. A peptide ligand according to Claim 6 or 7, in which the peptide ligand comprises:



9. A peptide ligand for use according to Claim 6, 7 or 8 which is for use in suppressing or treating ophthalmic disorders.

10. A peptide ligand for use according to Claim 9, in which the ophthalmic disorders

include exudative and/or inflammatory ophthalmic disorders, disorders related to impaired retinal vessel permeability and/or integrity, disorders related to retinal microvessel rupture leading to focal hemorrhages, back of the eye diseases, retinal diseases and front of the eye diseases and are selected from: age related macular degeneration (ARMD), exudative macular degeneration (also known as “wet” or neovascular age-related macular degeneration (wet-AMD), macular oedema, aged disciform macular degeneration, cystoid macular oedema, palpebral oedema, retinal oedema, diabetic retinopathy, acute macular neuroretinopathy, central serous chorioretinopathy, chorioretinopathy, choroidal neovascularization, neovascular maculopathy, neovascular glaucoma, obstructive arterial and venous retinopathies (e.g. retinal venous occlusion or retinal arterial occlusion), central retinal vein occlusion, disseminated intravascular coagulopathy, branch retinal vein occlusion, hypertensive fundus changes, ocular ischemic syndrome, retinal arterial microaneurysms, Coat’s disease, parafoveal telangiectasis, hemi-retinal vein occlusion, papillophlebitis, central retinal artery occlusion, branch retinal artery occlusion, carotid artery disease (CAD), frosted branch angitis, sickle cell retinopathy and other hemoglobinopathies, angioid streaks, macular oedema occurring as a result of aetiologies such as disease (e.g. diabetic macular oedema), eye injury or eye surgery; retinal ischemia or degeneration produced for example by injury, trauma or tumours, uveitis, iritis, retinal vasculitis, endophthalmitis, panophthalmitis, metastatic ophthalmia, choroiditis, retinal pigment epithelitis, conjunctivitis, cyclitis, scleritis, episcleritis, optic neuritis,

retrobulbar optic neuritis, keratitis, blepharitis, exudative retinal detachment, corneal ulcer, conjunctival ulcer, chronic nummular keratitis, thygeson keratitis, progressive mooren's ulcer, an ocular inflammatory disease caused by bacterial or viral infection, and by an ophthalmic operation, an ocular inflammatory disease caused by a physical injury to the eye, a symptom
 5 caused by an ocular inflammatory disease including itching, flare, oedema and ulcer, erythema, erythema exsudativum multiforme, erythema nodosum, erythema annulare, scleroedema, dermatitis, angioneurotic oedema, laryngeal oedema, glottic oedema, subglottic laryngitis, bronchitis, rhinitis, pharyngitis, sinusitis, laryngitis or otitis media.


11. A peptide ligand for use according to Claim 10, in which the ophthalmic disorder is
 10 diabetic macular edema.

12. Use of a peptide ligand according to any of Claims 1 to 4 in the preparation of a medicament for the treatment or suppression of inflammatory states, allergic hypersensitivity, cancer, bacterial or viral infection, ophthalmic disorders or autoimmune disorders.

13. Use of a peptide ligand according to any of Claims 1 to 4 in the preparation of a
 15 medicament for the treatment or suppression of ophthalmic disorders.

14. Use of a peptide ligand according to Claim 12 or 13, in which the peptide ligand comprises: Cys Ser1 Phe2 Aze3 Tyr4 HArg5 Cys Ala(ψ CH₂NH)6 His7 Gln8 Asp9 Leu10
 Cys.

15. Use of a peptide ligand according to Claim 12, 13 or 14, in which the peptide ligand
 20 comprises:



16. Use according to any of Claims 13 to 15, in which the ophthalmic disorders are as set out in Claim 10.
17. Use according to Claim 16, in which the ophthalmic disorder is diabetic macular edema.